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Abstract 
Blood transfusion is known to improve graft survival in renal transplant 
patients. The exact mechanism(s) by which blood transfusion confers this 
improved graft survival is still unknown, but some postulate that the presence 
of antibodies to idiotypic determinants of anti-HLA antibodies plays an 
important role. The aim of this project is to study the relationship between 
transfusion and the level of anti-idiotypic antibodies (anti-Ids) against anti-HLA 
antibodies in renal transplant patients and its effect on graft survival. 
An enzyme immunoassay based upon the ELISA principle was developed 
to detect anti-Ids to 9 anti-HLA antibodies in 101 renal transplant patients (48 
cadaveric donors [CD] and 53 living donors [LD]). Anti-HLA antibodies were 
purified by affinity chromatography and pepsinized to produce F(ab')2. 
Purified F(ab')2 were then used to coat microplate, and the binding of the 
corresponding anti-Ids in serum samples to the anti-HLA F(ab')2 was detected 
spectrophotometrically. The optimal condition of the assay was empirically 
obtained. 
The highest anti-Ids level found in each patient was measured. Renal 
transplant patients were categorized into various groups, namely: LD and CD, 
transfused and non-transfused, and the anti-Ids level of each group were 
compared with normal controls and also with each other. 
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In 26 transplant patients whose blood samples were available both before 
and after transplant, the temporal study showed that most patients reached 
their peak anti-Ids level within the first 100 days after transplantation. 
In comparison with normal controls, higher level of anti-Ids ip < 0.05) 
was found in transplant patients. LD transplant patients were less likely to have 
significantly high anti-Ids than CD transplant patients. Transplant patients with 
pre- and post-transplant transfusion had anti-Ids notably increased {p < 0.05), 
but the peroperative transfused group had comparable level with the normal 
controls (p > 0.1). 
High but not significantly elevated anti-Ids level was found in transfused 
transplant patients than non-transfused transplant patients (p > 0.1), There 
was also no significant increase of anti-Ids in transplant patients with various 
transfusion modalities (p > 0.1). 
Graft rejection occurred more frequently in non-transfused than 
transfused CD kidney recipients (p < 0.05), but there was no significant 
difference encountered in LD kidney recipients (p > 0.05). The average 
rejection episodes per patient were notably higher in non-transfused transplant 
patients {p < 0.01). 
The graft failure rates were 5.66% (3/52) and 20.83% (10/48) for LD and 
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CD kidney recipients respectively. The overall failure rate was 12.87% (13/101). 
CD kidney recipients were 3.68 times more vulnerable to graft failure than their 
LD transplant counterparts (10/48 in CD transplant versus 3/53 in LD 
transplant). Chi-squared analysis showed that graft survival was related to 
transfusion (p < 0.05). 
This study demonstrated the level of anti-Ids was higher in transplant 
patients than normal subjects, and an association between blood transfusion and 
a higher level of anti-Ids. It also showed that transfused transplant patients had 
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1.1. Idiotype Network 
The discovery of antigenic determinants associated structurally with the 
hypervariable region of the immunoglobulin molecule in human by Kunkel and 
co-workers^ as well as similar findings in rabbits by Oudin and MichaeP in 1963 
led to the description of idiotype. 
From Greek, "idios" means "of one's own or individual". An idiotype 
is a composite of idiotopes (antigenic determinants) located either in the 
complementarity determining regions of antibody combining sites (Figure 1.1) 
or the variable regions of antigen receptors of B and T lymphocytes. Whereas 
an antibody or a cellular receptor is regarded an immunogen, it possesses 
numerous antigenic determinants towards which specific antibodies can be 
elicited. Despite being idiosyncratic in nature，an idiotype may be shared, as 
a whole or in part, with other antibodies or cellular receptor molecules raised 
in response to a specifically immunological challenge within an individual or 
group of individuals, and leads to the semantic terminology of private (unique) 
and public (cross-reactive) idiotype respectively^. Antibodies with different 
antigenic specificity may share idiotypic determinants. On the contrary, 
antibodies to the same or slightly different epitodes on the same antigen may not 
necessarily share idiotype. 
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Idiotype Paratope 
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Antibody Idlotopes Epitope 
Hypervariable 
Regions 
Figure 1.1. Schematic presentation of antibody nomenclature. 
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Idiotypes are recognized and defined by antibodies, B-cell antigen 
receptors (membrane-bound immunoglobulins) and T-cell antigen receptors 
(TcRs). These antibodies, B or T cells which direct against and bind to 
idiotypes are designated as anti-idiotypes. The distinction between idiotype and 
anti-idiotype is merely operational. Any idiotype of an antibody, or of an 
antigen receptor of B and T cells, can be employed as an immunogen to elicit 
a complementary humoral or cell-mediated immune response. 
A regulatory idiotype network of the immune system in a state of 
suppression is based upon the mutual recognition between idiotype and 
complementary anti-idiotype, both as free antibody molecules and/or cellular 
receptors on B or T cells. Normally these complementary clones within the 
immune system are exceedingly large and simultaneously present to maintain 
immune homeostasis'*; however, the equilibrium can be upset by foreign 
antigens. Extraneous antigens disrupt this balance through idiotypic-anti-
idiotypic (Abj - Abj) interactions by creating, from the immunology perspective, 
an excess of the internal image of antigens (Abz). Not only does the excess 
• •• X 
induce Ab! production against the externally derived antigens, but also the 
immoderate Abj stimulates a second excessive internal image of the antigen. 
This second set of antibody, i.e. Ab:，is then elicited against the idiotopes of 
Abj. This latter clone will in turn be regulated in the same fashion, creating 
what Jerne has called a web of V-domains (Figure 1.2), though, under normal 
condition, high concentration of an antibody directed against a particular 
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Abi Ah 2 Ab3 
I 
Anti-idiotype 
Ag ^ ^ ^ Idiotopes Anti-anti-idiotype 
Anti-idiotype 
Parallel 
‘ ^ ^ set 
Anti-anti-idiotype 
Figure 1.2. Jerne's network theory of the immune system. 
% 
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unique idiotype is normally not present due to the extreme heterogenicity of the 
variable region of immunoglobulin to induce a particular anti-Id. This process 
continues through successive but decreasing stages of Abg, Ab* to Ab„, till the 
system again retains a state of stable equilibrium. In such a way, the immune 
system is not only connected but accommodated within its repertoire of idiotypes 
and paratopes, a set of anti-idiotypes of all antigenic determinants that the 
system is likely to encounter in the external environment. 
Nobel Prize was awarded to Jerne not for any particular laboratory 
research, but for his powerful, bold, far-reaching network theory of immune 
system that concerned the spatial relationship of antigen receptors and antibody 
idiotypes and their roles in regulating the immune response^. The theory was 
based upon a number of observations in the literature pertaining to the 
occurrence of idiotypes and on specific properties of the immune system. While 
theoretical contributions in physics, chemistry and mathematics had been 
frequently so acclaimed, this prestige was firstly extended to biomedical science 
with Jerne's principle on immune network in 1984. 
Data from a large number of experiments support Jerne's general 
network concepts of immune system. Nevertheless, it has been recently 
envisaged among immunologists that the hypothesis can be more accountable 
and manageable with minor modifications^. Firstly, the immune responses 
induced through idiotypic immunizations are not open-ended as originally 
% 
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conceived, but composed of multiple mini-networks. Ahj induced by idiotype-
positive Abi elicits Ahj. Being similar to Ab,, Abj interacts with and neutralises 
the effects of Abj. Thus, the response seldom proceeds beyond Aba 
physiologically. Secondly, all idiotypes are not necessarily networked in an 
immune regulatory cascade. This is supported by the recognition that only a 
subset of germline-encoded, cross-reactive idiotypes acts as regulatory idiotypes. 
Thirdly, idiotypic connectivity is not confined to B cells. Idiotypes have been 
recently demonstrated in TcRs, and the sharing of regulatory idiotypes between 
immunoglobulins and TcRs is likely '^^ . Some TcRs can even directly interact 
with each other through shared idiotypic networks, though it is hard to be 
convinced unless a TcR idiotype is presented to an anti-idiotypic TcR as a 
processed linear peptide on a MHC molecule*. 
An antibody or immune receptor has 2 distinct properties as far as its 
idiosyncrasy is concerned: antigen-binding activity and idiotype. This is 
conceivable that antibodies directed against the paratope can display molecular 
mimicry of the original antigen. The possibility that these 2 properties of 
specific immune receptors may be related has led to numerous attempts to 
modify immune responses to specific antigens through the use of anti-
idiotypes''*". In the induction of the immune response to transplantation 
tolerance, idiotypic manipulation has been particularly appealing. Decrease of 
specific immune response has been found in separate experimental models"'* '^* .^ 
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1.2. Anti-idiotype Classification 
Anti-Ids are immunochemically heterogeneous. They can recognize 
idiotypes either associated with the complementarity determining regions or with 
the framework portions of the variable region of antibodies or antigen receptors 
(Figure 1.3). When the binding of Abi to idiotype-positive Abi is associated 
with the hypervariable segments, the binding is inhibited by the specific antigen 
or hapteni4. On the other hand, when Abj binds to idiotopes which are located 
on the framework regions，the binding is not antigen or hapten inhibitable^ .^ 
Furthermore, the ability of anti-Ids to elicit an antibody response is an other 
major characteristic for the taxonomy of Abj. 
Based upon their immunochemical and functional idiosyncrasies, anti-Ids 
are originally assorted into 2 categories, namely: Abj^  and Abj/j^ ®. The 
classification is subsequently expanded further with the addition of 2 more new 
categories; Abj^  and Ab!尸. 
Abja are antibodies which bind to the idiotype of the antigen receptor of 
B or T cells through their paratope - complementarity-determining region 
formed by the heavy and light chains. Abj^ can also bind to the paratope-
related idiotype outside the antigen combining site of Ab” These two categories 
of antibodies are specific for framework-associated idiotypes. The apparently 












conformational changes of Ab” Eventually the equilibrium constant and the 
affinity of Ab! to specific antigen or hapten can also be altered. 
Ab2Y is，in fact, a subcategory of the Abj^ . The idiotype to which Abj^  
binds is so close to the Abi paratope that it interferes with nominal antigen or 
hapten binding. In an other word, Abj^  is antigen- or hapten-inhibitive. It is 
recognized solely for experimental reasons to distinguish the so-called internal 
image of a special Abj^ ^^ . 
Abj^  is combining site associated. Its idiotype fits well as an antigen in 
the Abi paratope of antibodies, and B or T cells. Paradoxically Ab:终 may 
imitate the original epitope and contribute to the internal image. Antibodies 
bearing an idiotypic determinant which mimics the 3-dimensional structure of 
the antigen are also known as homobodies^ .^ These antibodies can mimic 
foreign antigens borne by viruses, parasites, protozoa and many other 
biologically active metabolites such as hormones^ .^ Like antigens or bio-
metabolites, Abj^  compete for binding to the antigen receptors of lymphocytes 
and other somatic cells. 
Abj, (epibodies) are capable to react with an antigen and with an idiotype 
of an antibody towards the same antigen*^ '^ ®. The peculiarity of Abj, was 
believed to be mimicry of the amino sequences and/or the 3-dimensional 
structures shared by an antigen and an idiotype of an antibody towards the 
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same antigen. They are originally described in a study which aimed at defining 
the idiotype of murine antibodies specific for the major cross-reactive idiotype 
of human IgM paraproteins exhibiting rheumatoid factor activity. An epibody 
can represent a link of connectivity between various mini-networks specific for 
foreign antigens and auto-antigens, a kind of "superantibody"�*. 
1.3. Blood Transfusion Effect 
Kidney transplantation is the most important and effective therapy for 
patients suffering from end-stage renal failure. Such patients are inevitably 
anaemic, and blood transfusion is quite often necessary prior to prospective 
renal transplantation, and apparently serves as an indispensable supplement to 
haemodialysis as well as an empirical subsidy to patient's well being. 
The effect of blood transfusion effect on renal transplantation has been 
controversial and confusing. The presence of lympho-cytotoxic antibodies 
against donor in the pre-transplant serum of the recipient with hyperacute renal 
rejection was suggested to be induced by blood transfusion". However, about 
a decade later it was observed that patients who had not received a pre-
transplant blood transfusion had poor renal graft survival and predisposed to 
subacute rejections^. 
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Following Opelz and his co-workers' striking report, the beneficial effect 
of pre-transplant blood transfusion on graft survival was also subsequently 
shown in animal models which included monkeys^�dogs^^'^^, mice^ ^ and rats^ .^ 
These observations led to a liberal and sometimes deliberate transfusion policy, 
which contributed to the improvement of renal transplant outcomes till the early 
1980s. 
In 1983, this beneficial effect of blood transfusion effect was 
overshadowed by the introduction of cyclosporin^^. Also in 2 multicenter studies 
separately conducted by the Scandinavian group^" and the Collaborative 
Transplant Study^S this transfusion effect appeared to have lost most of its 
importance in renal transplants performed in 1984 and 1985. On the contrary, 
the beneficial blood transfusion effect was consistently demonstrated in the 
Transplant Registry of the University of California at Los Angeles from 1980 
to 198732. 
1,4. Transfusion Protocol 
Though most experts are virtually convinced by the fact that pre-
transplant transfusion improves renal transplant survival, there is no unanimity 
among them as to what the best transfusion modality is. 
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One school of thought was headed by Opelz, who was the first to 
document clearly the beneficial pre-transplant transfusion effect^. He 
advocated at least 5 pre-transplant blood transfusions and they should be spaced 
at 2 to 3-month intervals. However, others contended that a single blood 
transfusion was enough and the effect was very long lasting^ '^^ "*. 
The scenario became even more complicated as the transfusion effect 
could also be shown in recipients who had received deliberate donor-specific 
transfusions^'. Patients administered approximately 300 mL donor-specific 
whole blood, on three separate occasions at 2-week intervals, had comparable 
graft survival to those who received kidneys from HLA-identical sibling donors. 
An analysis of data collected during the South Eastern Organ 
Procurement Foundation Prospective Study from 1977-1982 identified the 
relative effects of different blood products on graft survival in cadaveric donor 
renal transplant recipients?^ A significant increase in actuarial graft survival 
was seen in primary recipients who had pre-transplant transfusions with only 
frozen blood, washed blood, packed blood, or any combination of blood 
products as compared with those who received no transfusion. No blood 
product was found to provide a significantly greater increase in graft survival 
than any other blood product. The same was also found in re-grafted patients. 
On the other hand, several studies reported excellent results in enhancing 
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renal graft survival by employing a policy of random (third party) blood 
transfusion37，38’39. interestingly 2 recent reports show that the transfusion effect 
could only be detected in HLA-DR mismatched transplant recipients but not in 
HLA-DR-compatible t r a n s p l a n t s ^ 2 ’ 4 o jhis finding implies that HLA-DR 
matching masks the transfusion effect. 
There is also elusive and controversial evidence upon the timing of blood 
transfusion in acquiring the optimal effect. No significant difference is observed 
whether blood transfusions are given several months or just a few days prior to 
renal transplantation'^ *''* .^ Available data indicate that per-operative blood 
transfusions are also effective"^, though this could not be confirmed in 2 large 
series of patients"*^  ‘ � a n d per-operative transfusion merely exerts an effect 
intermediate between pre-transplant transfusion and no transfusion at all耗. 
Moreover, a significant improvement was obtained by per-operative transfusions 
for re-grafts'*^. 
The type of blood product responsible for producing the transfusion 
effect has not been fully elucidated, but nevertheless leucocytes are critical in 
achieving the beneficial effect. Both fresh blood and buffy coat are 
feasible幼，49,so. Platelets which only express HLA class 1 antigens was reported 
to be as effective as whole blood in improving renal graft survival in 
primatessi，s2. In man, however, platelet transfusions were not shown to achieve 
the effect and even produced a detrimental outcome幻’ 
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1.5. Mechanism of the Beneficial Transfusion Effect 
Despite the overwhelming data indicating the beneficial effect of blood 
transfusion in renal transplantation since 1973 and the general acceptance of 
liberal blood transfusion as a mean of immunological manipulation in renal 
transplantation, little is known about the underlying mechanism. Even after 
nearly 2 decades of investigation, the mechanism(s) has not yet been thoroughly 
clarified. The immunology concerned still remains as a phenomenology - an 
ever accumulating catalogue of phenomena and observations. Several 
hypotheses have been proposed; however, each of them probably works only in 
the certain particular experimental setting to account for the observed clinical 
effects. They include: donor selection, clonal deletion, suppressor cells 
induction, prostaglandins mediation, mixed chimerism motivation, Fc-receptor 
blocking antibodies stimulation and anti-idiotypic antibodies instigation. 
1.5.1, Donor Selection 
It has been postulated that the transfusion effect is just an artefact 
caused by the exclusion of antibody-producing responders. Approximately one 
third of multi-transfused prospective renal graft recipients become hyper-
immunized and sensitized against the presumed donor and cannot be 
transplanted^^. Thus, blood transfusion leads to the selection of patients who 
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cannot make donor-specific lympho-cytotoxic antibodies. 
However, it is inconsistent with the observation of excellent graft survival 
in patients with increased mixed lymphocyte culture responses after donor-
specific transfusion, whom should be regarded as high responders^^. Moreover, 
the concomitant use of donor-specific transfusion and immunosuppressive 
regime results in a marked reduction in donor-specific sensitization, and the 
high transplant success rate，under these circumstances, is similar to that of 
non-sensitized patients^ .^ A further argument against the selection of non-
responders is the very low risk of developing broadly reactive antibodies after 
random blood transfusion^®. Finally, improvement in graft survival after 
transfusion has been demonstrated even in HLA-identical recipient-donor pairs, 
to whom the donor selection hypothesis simply plays no role® .^ 
1.5,2. Clonal Deletion 
It has been suggested^^ that the primary function of transfusion is 
presumably to immunize patients and not to induce tolerance. Blood 
transfusion can be modelled as a priming event. When antigens on donor blood 
cells are in contact with recipient's specific antigen receptors of T or B cells, 
they will trigger clonal proliferation and activation. After transplant, the graft 
causes a re-stimulation and an anamnestic response with accelerated and 
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vigorous cell divisions. The concomitant high-dose massive immunosuppression 
at the time of transplant eliminates these rapidly proliferating specific reactive 
cell clones and leads to self tolerance. Time is probably important for removing 
rejection-causing clones but leaving suppressive ones intact, yet their relative 
proportions are the key in improving graft survivals. 
Immunosuppressive regime is mandatory in achieving the salutary 
transfusion effect. If immunosuppression was omitted, blood transfusion results 
in an accelerated rejection. Thus, transfusion or immunosuppression alone is 
ineffective. Transfusion effect materializes only with the synergy of 
immunosuppression^®. 
However, this hypothesis cannot account for the evidence found in animal 
models，in which intravenous injection of allogeneic lymphocytes in non-
immunosuppressed recipients has resulted in prolongation of allograft survival^*. 
In addition, blood transfusions have not shown changes in cellular immune 
responses in man". In experimental animal models, blood transfusion does not 
always elicit antibody production, and prolonged graft survival has been noted 
in recipients without the presence of any significant antibodj^ ，似.Moreover, 
blood transfusion does not always trigger allo-immunization. 
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1-5.3, Suppressor Cells Induction 
It has been well documented that one of the major functions of 
suppressor cells is to keep surveillance upon B and certain T lymphocytes, and 
hence indirectly controls and regulates antibody production and cellular 
functions respectively. 
There is good indication to suggest that blood transfusion can possibly 
mediate active immunologic unresponsiveness to donor's allo-antigens by the 
induction of either specific or non-specific suppressor cels似，• So far, most 
suppressor cells are T cells of either CD4-positive or CD8-positive subset, 
though some can also be prostaglandin-producing macrophages with the 
immunosuppressive reactivity?。,，*. 
However, there are still no firm data showing that prolongation of 
allograft survival is the result of suppressor cells which inactivate reactive T 
cells. In addition, there are 2 related problems with the study of suppressor 
cells. The first one is the limited access to or the absence of distinctive 
membrane markers. Due to the heterogenicity of suppressor cells, a good 
specific marker is at present virtually insurmountable without any unlikely 
contamination. The second problem is the difficulty in developing a reliable 
assay system. The most commonly used strategies in assay systems are in-vivo 
adoptive transfer investigations and in-vitro cell-mixing analysis. Due to ethical 
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consideration, in-vivo adoptive transfer studies which inevitably require certain 
extent of immunosuppression, such as low dose irradiation or chemotherapy can 
only be applied in animal models. On the other hand, in-vitro analysis of 
suppressor cells is particularly prone to artefactual errors such as lymphokine 
consumption or cytotoxic response by activated T cells^ .^ 
T-cell mediated suppression is merely determined by the way antigen is 
presented to the immune system. A subset of T cell activated earlier can exert 
a different immune response from the same T cell subset activated at a later 
stage. The order in producing different lymphokines during T-cell activation 
may govern whether the result is suppression or responsiveness. 
1.5.4. Prostaglandins Mediation 
Prostaglandin E, the prostanoid derivatives of arachidonic acid, is a 
product of the cyclo-oxygenase pathway and is known to have multiple 
immunosuppressive properties, including inhibition of lymphocyte mitogenesis 
and interleukin-2 production. Short-lived, antigen non-specific, suppressor T 
cell generation has also been attributed to high level of prostaglandin E乃.Yet 
non-specific transfusion-induced immunosuppressive mediators are thought to 
account for the beneficial effect of transfusion in prolongation of renal allograft 
survival7i’74’7s’76, 
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In animal model, significantly increased prostaglandin E synthesis in 
peritoneal macrophage after allogeneic blood transfusion suggests an 
immunosuppressive effect of the blood transfusion-prostaglandin interaction”. 
In man, a dose-dependent increase of prostaglandin synthesis after transfusion 
is also noted78. 
On the other hand, it is crystal clear that the nutritional variations of 
dietary lipids do indeed change prostaglandin metabolism and may have a 
significant effect on the immune system. Lipid substrate may eventually be 
metabolized through the lipoxygenase pathway to thromboxane and the 
leukotrienes, which have prodigiously stimulatory effects and outweigh the 
immunosuppressive activities of prostaglandin^'*. 
1.5.5. Mixed Chimerism Motivation 
The peripheral stem cells, though present in a small number in the 
transfused blood, can under certain conditions, dwell themselves in particular 
caches, induce low grade mixed allogeneic chimerism and promote immunologic 
tolerance*®'". 
The induction of low grade mixed chimerism may be influenced by the 
HLA disparity between donor and recipient. The lesser the HLA disparity, the 
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higher the chance for stem cells to implant themselves in privileged sites. They, 
together with their progeny, may be protected from immune attack by a veto-
like mechanism'^ '^ '* .^ Though the probability is extremely low, this process can 
be enhanced by T-cell depletion with monoclonal antibodies or mild 
pharmaceutical immunosuppression of the recipient. 
In animal model, mixed chimerism can be i n d u c e d 於抓*? . Sharabi and 
Sachs demonstrated stable allograft survival in mice across a complete H-2 
disparity by treatment with anti-CD4 + anti-CD8 monoclonal antibodies and 
low dose whole body irradiation followed by donor bone marrow transfusion於. 
Qin and co-workers described skin allograft tolerance by administration of anti-
CD4 + anti-CD8 monoclonal antibodies in combination with donor bone 
marrow®^ Mayumi and Good also showed that skin allograft tolerance in mice 
across H-2 and non-H-2 barriers could be induced by anti-Thy-1 treatment and 
donor bone marrow followed by cyclophosphamide*^. 
This hypothetical explanation to the beneficial blood transfusion effect is 
not without challenge. It has been argued that the tolerance may be due to the 
artefact of effective clonal deletion or anergy of immunocompetent CD4-positive 
cells to prevent detrimental rejection responses. Furthermore, it has been 
documented that the combination of T-cell purging by anti-T cell monoclonal 
antibodies and allogeneic bone marrow infusion has failed to induce chimerism 
or tolerance, but has resulted in sensitizing the recipient instead®*. 
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1.5.6. Fc-receptor Blocking Antibodies Stimulation 
The interaction of antibody-antigen complexes with cells of the immune 
system results in a wide array of responses ranging from effector functions such 
as antibody dependent cytotoxicity, mast cell degranulation and phagocytosis, 
to immuno-modulatory signals such as regulating lymphocyte proliferation and 
antibody secretion. All these interactions are initiated through the binding of 
the Fc-domain of antibodies or immune complexes to specialized cell surface 
receptors on haemopoietic cells such as monocytes and macrophages. 
Fc-receptor is a signal transducing molecule and is one of the paramount 
and indispensable domains essential for the processing of immune complexes 
within the immunity system. Fc-receptor blockage will hinder immune 
complexes manipulation and, in turn, lead to immuno-compromisation and 
immunologic tolerance eventually*^. 
The presence of humoral cytotoxic antibodies to the allograft recipient's 
lymphocytes has been reported prior to transplantation; however, some have 
been shown to be harmless^®. They react with both B and T cells from a panel 
of normal donors or, in some cases, with B lymphocytes alone, but not with 
lymphocytes from patients with chronic lymphocytic leukaemia^\ This finding 
indicates that the cytotoxic antibodies are not directed against HLA antigens, 
since cells from those leukaemic patients possess such antigens on their surfaces. 
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Non-cytotoxic allo-antibodies that presumably block Fc-receptor sites on 
B lymphocytes and macrophages following blood transfusions are demonstrated 
in prospective transplant patients with improved allograft survial，!’幻’似 and 
during pregnancy^^. Fc-receptor blocking antibodies are also detected in long-
term survivors of renal allografts^. 
On the contrary, an overall decrease of graft survival in the presence of 
B lymphocyte antibodies has been reported打.The development of donor 
specific B lymphocyte antibodies after renal transplantation also casts much 
doubt upon this hypothesis卵，外• 
1,5.7. Anti-idiotypic Antibodies Instigation 
Theoretically, the existence of an anti-idiotypic network provides an 
exquisite way to dampen immune responses^ ®®. The formation of anti-idiotypes 
(Abj) directed against the variable regions of antibody combining sites or 
antigen receptors of T lymphocytes (Ab!) is frequently considered as an 
important explanation for the beneficial transfusion effect in allograft tolerance. 
The clonal expansion of donor-reactive T cells in response to donor blood elicits 
a compensatory proliferation of anti-idiotypic B cells which produce antibodies 
that block the antigen-specific T-cell receptor or circulating antigen-specific 
antibodies at the time of engraftment. Donor-reactive T cells are, in fact, not 
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completely eliminated by post-transplant immunosuppression, but instead are 
held in check by the anti-Ids. 
Certain data suggest that anti-idiotypic antibodies directed against 
antigen recognition sites on T-cells in human can be induced by blood 
transfusion他.Anti-Ids developed during the immediate post-transplant period 
in hepatic transplantation are capable to immuno-precipitate T-cell receptor*似. 
In addition, the presence of anti-Fab antibodies and significantly higher 
anti-F(ab)2^ antibodies in pre-transplant sera are shown to correlate with better 
graft siirvival^ ，i°^  The development of anti-Ids directed against anti-HLA 
antibodies after donor-specific transfusions is consistent with the hypothesis that 
anti-Ids down-regulates allo-immunity^® .^ 
However, it has been reported that anti-idiotypic antibodies enhance and 
potentiate, rather than inhibit, the Abi activit/® '^'® '^'®'. In addition, 
immunologically mediated renal diseases can be modulated by interfering with 
the mechanism of production of autoantibodies of specific anti-idiotypic 
reactivityi^. Furthermore, there are no studies which prove that anti-Ids can 
specifically prolong allograft survival. 
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1.6. Study Aims 
One important goal of transplantation immunology is to make possible 
successful tissue or organ transplantation without long-term need of 
immunosuppression. Since 1973, blood transfusion has been appreciated as one 
of the simplest and most pragmatic ways to induce allograft tolerance in renal 
transplantation. Recently this beneficial effect of blood transfusion is being 
challenged, and doubts have been casted upon such practice. 
The main theme of this project was to study the relationship between 
blood transfusion and the prevalence of anti-Ids against anti-HLA antibodies in 
serum samples of renal transplant recipients. A comparison was also made to 
the levels of anti-Ids in renal transplant patients and those found in a normal 
control group. 
Moreover, quantitative comparison of anti-Ids was studied in the 
following categories: transfused renal transplant recipients versus a normal 
control group, transfused versus non-transfused patients with kidney transplant, 
and non-transfused renal transplant recipients versus a normal control group. 
Correlations of graft rejection and graft survival with transfusion were also 
examined. 
Inference drawn from the findings of this project could shed some light 
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on whether blood transfusions were indeed beneficial to renal transplant 
recipients and should remain a viable therapeutical adjunct in these patients. 
1-7. Technical Strategy 
The techniques involved in this project were basically divided into 2 main 
sections. The first section primarily dealt with the purification and preparation 
of F(ab')2 from Ab .^ The second portion employed ELISA to capture and 
measure A b � i n the serum samples (Figure 1.4). 
Nine human polyclonal anti-HLA antisera which are specific and reactive 
to the most frequently expressed antigens of HLA-A, B and DR loci in the study 
patient population were used as the source of Ab” They were passed through 
chromatography columns packed with purified Protein A covalently coupled to 
agarose. Each purified Ab^ after elution was then dialyzed and pepsinized to 
generate F(ab')2. The yield was passed through the Protein-A column to remove 
the pFc' contamination. The affinity purified F(ab')2 was further dialyzed to 
remove any residual unbound pFc' and extensively digested small fragments to 
eliminate any undesirable interference in the subsequent assay. 
A method based upon the ELISA principle was then utilized to evaluate 
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Figure 1.4. Flow chart showing the technical procedure involved In measuring 
anti-idiotypic antibodies against anti-HLA antibodies. 
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microplate and casein was utilized to inhibit non-specific bindings (see Method 
section 2.2.4). Prospective Abj in the serum samples bound to Ab^  F(ab')2 
were detected by Fc-specific, horse-radish peroxidase conjugated goat anti-
human IgG and read spectrophotometrically with the addition of o-
phenylenediamine dihydrochloride (Figure 1.5). 
In order to make the analysis valid, a checkerboard titration was 
performed with a serum sample known to have a high anti-F(ab')2 activity. 
Optimization of the study was resolved for the amount of coating F(ab')2, nature 
and concentration of the blocking casein, dilution of the analyzing serum sample 
and the detector antibody (see Chapter 4). 
Ab2 against 9 Abi were studied in 151 serum samples from 101 patients. 
Since temporal study of Ab�was possible for a number of patients, those with 
highest Ab2 were enrolled into the Ab�kinet ic study and statistical 
manipulation. Moreover, potential interference due to anti-casein was also 
offset (see Chapter 6). 
Due to the non-availability of appropriate Ab�standards rendering the 
absolute quantitation impossible, strict quality controls on the inter-assay and 
intra-assay precision were carried out throughout the study to guard against any 
significant fluctuation of OD readings due to technical variables, and thereby 
validated the measurement of anti-Ids. 
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Figure 1.5. Diagramatic presentation of ELISA. 
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Chapter 2 
Materials and Methods 
2. Materials and Methods 
2.1. Materials 
2.1.1. Patient Population 
Totally 101 ethnic Chinese patients in Hong Kong were recruited in this 
study with 48 having received cadaveric donor kidney and 53 transplanted living 
donor renal allografts. All grafts were ABO-compatible. Patient history such 
as sex and age, date of transplant, ABO and HLA typings and compatibilities, 
allo-immunization, graft rejection episodes, immunosuppressive drugs taken, 
renal biopsies, date and number of blood/blood products transfused, and any 
graft failure were all retrieved retrospectively. None of the patients had 
agammaglobulinaemia or paraproteinaemia. 
2.1.2. Normal Control Group 
Thirty-one apparently healthy subjects, 13 to 50 years old, without any 
history of organ transplant or blood transfusion, were recruited as the normal 
control group. The females in the control panel were nulliparous with no 
abortion history. 
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2.1.3. Serum Samples 
Pre-transplant and post-transplant venous blood samples were drawn at 
weekly intervals. Venous blood samples were also collected from the normal 
control group. Sera were saved, dispensed into aliquots and stored at -70®C till 
tested. 
2.1.4. Additional Specimens 
Two different serum samples from patients suffering from systemic lupus 
erythematosus known to have anti-F(ab')2 reactivity which were gifts from Mr. 
Albert Chan, Senior Research Technician of Renal Laboratory, under the 
auspices of Dr. Ignatius K.P. Cheng, Senior Lecturer of Department of 
Medicine, University of Hong Kong, were incorporated as positive controls in 
this study. One was employed in the optimization of the ELISA system while 
the other was used as an intra-assay and inter-assay positive control. 
2.1.5. Chemicals 
The following chemicals were obtained from Sigma, St. Louis, MO 
63178, USA : 
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-Bovine serum albumin 
-Crystallized and lyophilized Pepsin with 2500 - 3500 units per mg 
protein 
-Carbonate buffer capsules of 0.05 M, pH 9.6 
-p-Nitrophenyl phosphate tablets of 5 mg each 
-Phosphate-citrate buffer capsules with 
0.012% sodium perborate of 0.05 M at pH 5.0 
-o-Phenylenediamine dihydrochloride tablets of 30 mg 
-Monolaurate (Tween 20) 
-Tris (hydroxymethylaminomethane) 
The following were obtained from BDH, Dorset BH12 4NH, England : 
-Casein soluble light white 




-Sodium dihydrogen phosphate 
-Sodium hydroxide 
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The following lyophilized human polyclonal antisera were from Hoechst-
Behring, Marburg D-3550, Germany : 
-ant i -HLA-Al l Lot # 021108C 
-anti-HLA-A24 Lot # 022401M 
-anti-HLA-A2+A28 Lot # 028105C 
• anti-HLA-B17 Lot # 021710C 
-anti-HLA-Bw22+B7 Lot 特 028404B 
-anti-HLA-B40+B13 Lot # 028803A 
-anti-HLA-DR2 Lot # 070205E 
-anti-HLA-DR4 Lot # 070406G 
-anti-HLA-DR7 Lot # 070706K 
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Affinity purified lyophilized goat anti-human IgG of 0.9 mg/mL, Lot 林 
061891J7，which is Fc-specific and conjugated with horse-radish peroxidase with 
suggested working dilution from 1:5000 to 1:100,000 for enzyme immunoassay 
was from Chemicon, Temecula, CA 92390，USA. 
Affinity isolated goat anti-human IgG, Lot # 59F4813，which is Fab-
specific and conjugated with alkaline phosphatase with suggested minimum 
working dilution 1:1000 was from Sigma, St. Louis, MO 63178，USA. 
2.1.7, Buffers 
All solutions were prepared from deionized and distilled water with 
^Analar' grade chemicals : 
Acetate Buffer, 20 mM pH 4.0 
CHjCOONa 1.64 g/L 
C H 3 C O O H 1 . 2 0 g / L 
One volume CHjCOONa solution was mixed with 2 volumes of 
C H 3 C O O H solution till pH 4.0. 
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Carbonate Buffer, 50 mM pH 9.6 
One capsule of carbonate buffer (Sigma, USA) was dissolved in 
100 mL deionized and distilled water. 
Carbonate Buffer with 5 mM MgCl】，25 mM pH 9.6 
One capsule of carbonate-bicarbonate buffer (Sigma, USA) and 
0.13 g MgCl2.2H20 were dissolved in 200 mL deionized and 
distilled water. 
Glycine-HCl Buffer, 20 mM pH 2.5 
Glycine 1.50 g/L 
pH adjusted to 2.5 with 0.02 M HCl 
Phosphate Buffer Saline (PBS), 0.2 M pH 7.4 
K2HPO4 26.60 g/L 
KH2PO4 8.00 g/L 
NaCl 8.77 g/L 
pH titrated to 7.4 with 1 M NaOH or HCl 
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PBS, 10 mM pH 7.4 
K2HPO4 1.33 g/L 
KH2PO4 0.40 g/L 
NaCl 8.77 g/L 
pH adjusted to 7.4 with 1 M NaOH or HCl 
Phosphate Buffer Saline-Tween (PBST) 
PBS 10 mM pH 7.4 1 L 
Tween-20 0.5 mL 
Phosphate Buffer Saline-Casein (0.5% PBSC) 
PBS 10 mM pH 7.4 1 L 
Casein 5 g 
pH adjusted to 7.4 with 5 M NaOH 
Phosphate Buffer Saline-Casein (2.5% PBSC) 
PBS 10 mM pH 7.4 1 L 
Casein 25 g 
pH adjusted to 7.4 with 5 M NaOH 
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Phosphate-Citrate Buffer with 0.012% Sodium Perborate, 50 mM pH 5.0 
One capsule of phosphate-citrate buffer (Sigma, USA) 
was dissolved in 100 mL deionized and distilled water. 
Tris-HCl Buffer, 10 mM pH 8.0 
Tris 1.21 g/L 
pH adjusted to 8.0 with 1 M HCl 
2.1.8, Consumables 
Affinity columns of 2.5 mL immobilized Protein A covalently coupled to 
agarose with binding capacity of 12-15 mg human IgG per mL of gel were from 
Pierce, Rockford, IL 61105，USA. 
Dialysis cellulose membrane, Model Spectra/Por 7，with MW cutoff 
50,000, volume capacity 0.46 mL/cm, cylinder diameter 7.6 mm and flat width 
12 mm was from Spectrum, L.A. 90054, USA. 
Micro-concentrators, Centricon-30 of MW cutoff 30,000 were from 
Amicon, Beverly, MA 01915, USA. The IgG recovery in the retentate was 96% 
of the starting concentration. 
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Microtitre plates, Model Immulon 3，in an arrangement of 96 miniature 
polystyrene flat bottom wells of volume capacity of approximately 0.4 mL each 
were from Dynatech, Chantilly, VA 22021, USA. 
Polypropylene pipette tips with good precision were from Bio-Rad, 
Richmond, CA 94802, USA. 
2.1.9. Apparatus and Equipment 
High-precision adjustable Gilson pipettors, Models PIO, P20, P200 and 
PIOOO ranging from 10 to 1000 uL for serum and reagent dispensing and 
sampling were from Gilson, Villiers-le-Bel 95400, France. 
A multichannel motorized pipette, Model EDP-Plus M8 from Rainin, CA 
94608，USA was utilized in multiple sampling and dispensing in the ELISA. 
A compact bench-top hot air incubator with shaker, Model LT Biomax 
500 (Life Technologies, Singapore) was employed in all incubations. 
A programmable bench top centrifuge with a fixed-angle rotor, Model 
Labofuge 200，was from Heraeus Sepatech, Germany. 
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Quartz cuvette and a diode array spectrophotometer, Model 8452A from 
Hewlett Packard linked to an IBM compatible PC, Model Commodore PC 40-
III, were used to read absorbance (OD). The data capture was carried out with 
Hewlett Packard software and hard copies were available with an Epson LX-800 
dot matrix printer. 
The following equipment were obtained from Dynatech, Chantilly, VA 
22021，USA : 
-programmable and automatic 96-channel AM56 Ultra Washer II 
completed with vacuum pressure unit, liquid and vacuum bottles, bottle 
holder and all necessary tubings and connections. 
-programmable and automatic MR5000 microplate reader linked with 
an Epson LX-800 dot matrix printer. 
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2.2, Methods 
2.2.1. Purification of Human Polyclonal Anti-HLA Antisera 
2.2.1.1. Affinity Chromatography 
Lyophilized human polyclonal anti-HLA antisera (Hoechst-Behring, 
Germany) from primiparous and multiparous females were reconstituted with 
0.5 mL deionized and distilled water, then were allowed to pass through the 
column packed with puriHed Protein A covalently coupled to agarose (Pierce, 
USA) under unit gravity with an hourly flow rate of 18 mL. The column was 
washed with 3 mL 10 mM Tris buffer pH 8.0 and the effluent was recycled 
twice into the column to maximize the IgG capture. The column with bound 
IgG was washed with Tris buffer pH 8.0 till no residual protein contaminant 
was detected as monitored by the OD of the effluent at 280 nm. The column 
with bound IgG was eluted with 20 mM glycine buffer pH 2.5, The IgG eluate 
of 0.5 mL fraction was allowed to drop into equal volume of 0.2 M phosphate 
buffer pH 7.4 for immediate neutralization. Fractions with OD greater than 
0.05 at 280 nm were pooled. 
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2.2.1.2. Dialysis 
Purified IgG was dialyzed against at least 2000 x volume 10 mM PBS pH 
7.4 at 4�C using dialyzing tubing (Spectrum, USA) of 50,000 MW cutoff for 24 
hours with 4 changes of buffer and continuous stirring. 
2.2.1.3. Concentration 
Approximate 2 mL purified antibody was added to a micro-concentrator, 
Centricon-30 (Amicon, USA) of 30,000 MW cutoff and spun with a fixed-angle 
rotor centrifuge, Labofuge 200 (Heraeus Sepatech, Germany) at 3000 x g for 15 
minutes. Filtrate was discarded. Micro-concentrator was then inverted and 
spun at 1000 x g for 2 minutes to transfer the concentrate into the retentate cup 
and saved for later use. 
2.2.1.4. Quantitation 
The final volume of the concentrated IgG was measured and the OD was 
read at 280 nmina quartz cuvette against 10 mM PBS pH 7.4 as reagent blank 
using a spectrophotometer (Hewlett Packard, USA) linked to an IBM compatible 
PC (Commodore, USA) and a dot matrix printer (Epson, USA). The purified 
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quantity of anti-HLA antibody was computed with the coefficient of extinction 
of human IgG^^ ®. 
2.2.2. Generation of F(ab')2 fragments from the Purified Human 
polyclonal anti-HLA antibodies 
2.2.2.1. Buffer Exchange 
Concentrated IgG in 10 mM PBS was dialyzed against 2000 x volume 20 
mM sodium acetate buffer pH 4.0 at 4®C for 6 hours to have thorough buffer 
exchange. 
2.2.2.2. Pepsin Digestion 
The non-specific protease which is active only at acid pH and is 
irreversibly denatured at neutral or alkaline pH cleaves normally at the C-
terminal side of the inter-heavy chain disulphide bonds and produces a bivalent 
antigen binding fragment, F(ab')2，with MW about 105,000. The Fc portion 
undergoes extensive degradation into pFc' of MW 27,000 and small peptides. 
Crystalline pepsin (Sigma, USA) was added to the purified IgG in 20 mM 
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acetate buffer pH 4,0 in a ratio of 1:50 (w/w) and incubated for 20 hours at 
37®C. Digestion was stopped by adding 10 mM Tris buffer pH 8.0. 
2.2.2.3. Purification of F(ab')2 
To remove the undigested IgG, pFc'-fragments and extensively digested 
small polypeptides, the preparation was run through a Protein A column 
(Pierce, USA) equilibrated with 10 mM PBS pH 7.4. Those Protein A-unbound 
fractions of F(ab')2 of MW about 105,000, the likely contamination with pFc'-
fragments of MW 27,000 and extensively small polypeptides, with OD greater 
than 0.05 were pooled, dialyzed against 10 mM PBS pH 7.4 in dialysis tubing 
of MW cutoff 50,000 and concentrated as stated in Method Sections 2.2.1.2. and 
2.2.1.3. The yield was dispensed into aliquots and stored at -70°C for later use. 
2,2.3. Enzyme-Linked Immunosorbent Assay for anti-Idiotypes 
against anti-HLA antibodies 
2.2.3.1- Optimization 
To ensure that the anti-idiotypes in test sera could be captured by an 
optimal amount of anti-HLA F(ab')2，a checkerboard titration was performed 
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on 1 of the 2 serum samples known to have a high anti-F(ab')2 activity (see 
Material section 2.1.4). 
One hundred uL of 1，2，5，10 to 20 ug/mL specific anti-HLA F(ab')2 in 
0.05 M carbonate buffer pH 9.6 were used to coat microtitre plates (Immulon 
3，Dynatech Lab., USA) overnight at 4�C. The plates were then washed 10 
times in 10 mM PBS pH 7.4 with 0.05% Tween (PBST). Non-specific binding 
was blocked with 200 uL of 2.5% casein (BDH Chemicals Ltd, England) in 10 
mM PBS pH 7.4 (PBSC) for 1 hour at 3TC. After washing, 100 uL of 1:50 to 
1:400 normal serum control and serum control with high anti-Ids in 0.5% PBSC 
were added in quadruple and incubated for 3 hours at 37®C. The plates were 
washed again 10 times with PBST. Hundred uL of 1:5000 to 1:40000 Fc-
specific，horse-radish peroxidase conjugated goat anti-human IgG (Chemicon, 
USA) in 0.5% PBSC was added and incubated 2 hours at 3TC. Plates were 
subsequently washed 10 times with PBST and developed using 100 uL of 0.6 
mg/mL o-phenylenediamine dihydrochloride in 50 mM phosphate-citrate pH 5.0 
containing 0.012% sodium perborate (Sigma, USA) as a substitute for H2O2. 
The 7-minute reaction was stopped by adding 50 uL of 4 M H2SO4 and the 
orange-brown end-point was read spectrophotometrically with the Dynatech 
MR5000 microplate reader (Dynatech, USA) at 492 nm against the reagent 
blank; i.e. the OD generated from wells without the addition of test serum. 
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2.2.3.2. Quality Control 
2.2.3.2.1. F(ab')2 Specificity 
One hundred uL of 2 ug/mL specific anti-HLA F(ab')2 in 0.05 M 
carbonate buffer pH 9.6 was used to coat microtitre plates overnight at 4®C. 
The plates were then washed 10 times in PBST. Non-specific binding was 
blocked with 200 uL of 2.5% PBSC for 1 hour at 3TC. After washing, 100 uL 
of 1:2000 goat anti-human F(ab')2 conjugated with alkaline phosphatase (Sigma, 
USA) in 0.5% PBSC was added and incubated for 2 hours at 3TC. The plates 
were then washed and developed using 100 uL of 1 mg/mL disodium p-
nitrophenyl phosphate (Sigma, USA) in 25 mM bicarbonate buffer pH 9.6 with 
5 mM MgCl2. The reaction was stopped by adding 50 uL 0.75 M NaOH after 
20 minutes. The yellow colour of nitrophenol was measured at 405 nm with the 
microplate reader against the reagent blank, i.e. the OD generated from wells 
without the coating of F(ab')2. 
2.2.3.2.2. Fc-fragments Contamination 
The testing procedure for the likely contamination by the residual 
undialyzed Fc-fragments in the F(ab')2 preparation was similar to that described 
in Method Section 2.2.3.2.1., except 100 uL of 1:30000 HRP-AHG was directly 
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added after blocking and OPD was used as the chromogenic substrate for colour 
development. The 7-minute reaction was stopped by the addition of H2SO4 and 
the OD was read. 
2.2.3.2.3. Precision Test 
To guard against the precision and reproducibility of the assay, positive 
serum controls with high anti-F(ab')2 activity and reagent blanks in parallel 
with the test samples were performed within and between runs of the testing 
protocol. The data were compiled and C.V.s were calculated. Test results from 
batches that generated control OD values which fell out of 95% significance 
interval were discarded and the testing was repeated. 
2.2.4. Anti-Casein Interference 
Due to the prevalence of intolerance of milk and milk products intake 
from ethnic Chinese and the possibly formation of the corresponding nuisance 
anaphylactic antibodies, the possible interference to the anti-Ids assay caused by 
anti-casein was also under consideration. 
Wells without the coating of anti-HLA F(ab')2 were blocked with 200 uL 
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of 2.5% PBSC for 1 hour at 3TC, washed, and 100 uL of 1:100 test serum in 
0.多％ PBSC was added in duplicate and then subsequently processed in the same 
way as cited in Method section 2.2.3.2.2. The orange-brown end-point against 
the reagent blank yielded the OD caused by anti-casein in the test sera. 
In order to minimize the possible interference, auto-control for anti-
casein was run in parallel with test for Abj. Correction was made by 
subtracting the anti-casein background from that of test. 
2.2.5. Test Protocol 
The testing procedure was the same as stated in Method section 2.2.3.1., 
except with 100 uL of 2 ug/mL anti-HLA F(ab')2 for plate coating, 100 uL of 
1:100 for assaying serum samples and 100 uL of 1:30000 HRP-AHG for the 
abducted anti-Ids. Positive controls were run in parallel. All tests were 
performed in quadruple. 
2.3. Statistical Analysis 
The comparison involved 2 sets of separate, independent samples from 
assumed normal distributions, namely; renal transplant patients versus normal 
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subjects, transfused renal graft recipients versus non-transfused counterparts, 
and non-transfused transplant patients against normal subjects as well. 
Z- testin was applied to manipulate the naturally unpaired data. For the 
spare data which the total degree of freedom was less than 50, the unpaired 
Student's t- test^ ^^ was used. With data that revealed apparent difference in the 
variances of 2 naturally unpaired samples, F- test was utilized^. When the 
sample sizes were very small，Mann-Whitney U - Wilcoxon Rank Sum W Test 




Anti-HLA IgG and F(ab')2 
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3- Purification of Anti-HLA IgG and F(ab')2 
3.1. Immunoglobulin Concentration 
Polyclonal anti-HLA antisera of known specificities from commercially 
available lyophilized human sera of primiparous and multiparous females were 
affinity-purified by passing through columns packed with purified Protein A 
covalently coupled to agarose. The respective anti-HLA IgG harvested from 0.5 
mL lyophilized ampoules are shown in Table 3.1. The yield, ranging from 2.14 
to 4.34 mg, was quantitated by means of the following equation and the human 
IgG extinction coefficient. 
Yield (mg/mL) = A280 / EC x DF 
where A280 is the OD of yield at 280 rnn， 
EC is the human IgG extinction coefficient of 1.43, and 
DF is the dilution factor. 
3.2. F(ab')2 Specificity 
An absolute method for protein determination"^ based on the difference 
in OD values at 235 and 280 nm was adopted for the F(ab')2 quantitation in this 
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Table 3.1. Harvest of anti-HLA IgG and F(ab')2 from 0.5 mL lyophilized 
human anti-HLA antisera 
Yield (mg) 
Antibody Specificity IgG F(ab')2 
Anti-HLA-All 3.42 1.00 
Anti-HLA-A24 2.14 0.55 
Anti-HLA-A2+A28 2.79 0.72 
Anti-HLA-B17 3.18 1.25 
Anti-HLA-Bw22+B7 4.34 1.77 
Anti-HLA-B40+B13 3.08 0.82 
Anti-HLA-DR2 3.63 1.10 
Anti-HLA-DR4 2.79 0.79 
Anti-HLA-DR? 2.71 0.72 
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project. The equation used is as follow: 
Protein concentration (mg/mL) = (A235 - A280) / 2.51 
where A235 and A280 are the OD values at 235 and 280 nm respectively. 
The mean recovery of the digested product, F(ab')2 after pepsinization 
i is 30.29%; ranging from 25.70 to 40.78% (Table 3.1). The F(ab')2 preparations 
of 9 purified Ab! were checked for any noticeably adverse over-degradation and 
possible loss of Fab immunochemical reactivity after digestion, and the results 
were clearly indicated in Table 3.2. The mean OD readings detected by alkaline 
phosphatase-conjugated, Fab-specific goat anti-human IgG on 9 Ab! F(ab')2 
preparations of 0.2 ug (2 ug/mL) were significantly higher than those of the 
reagent blank after a 20-minute incubation (p < 0.01). The Fab specificity was 
guaranteed. 
3.3, Fc-fragments Contamination 
As shown in Table 3.3, the mean OD readings generated by horse-radish 
peroxidase-conjugated, Fc-specific goat anti-human IgG on 9 Ab^ F ( a b ' ) 2 
preparations of 0.2 ug were extremely low; ranging from 0.041 to 0.063. The 
likely Protein A-unbound Fc-fragments and those extensively pepsin-digested but 
undialyzed small fragments were low in these 9 Ab^ F(ab')2 preparation. 
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Table 3.2. Mean absorbance of F(ab')2 preparations detected by Fab-
specific alkaline phosphatase-conj ugated goat anti-human IgG 
F(ab')2 Specificity n OD SD SEM %CV 
Anti-HLA-All 24 0.274 0.008 0.002 2.81 
Anti-HLA-A24 24 0.253 0.006 0.001 2.20 
Anti-HLA-A2+A28 24 0.275 0.006 0.001 2.09 
Anti-HLA-B17 24 0.255 0.008 0.001 3.14 
Anti-HLA-Bw22+B7 24 0.278 0.006 0.001 2.21 
Anti-HLA-B40+B13 23 0.271 0.011 0.002 3.98 
Anti-HLA-DR2 24 0.258 0.006 0.001 2.47 
Anti-HLA-DR4 24 0.283 0.007 0.002 2.61 
Anti-HLA-DR7 24 0.248 0.006 0.001 2.61 
Reagent Blank 50 0.104 0.006 0.001 5.70 
where : 
n = number of tests 
OD = Mean Absorbance 
SD = Standard Deviation 
s SEM = Standard Error of Mean 
%CV = Coefficient of Variation in percentage 
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Table 3.3. Mean absorbance of F(ab')2 preparations detected by horse-
radish peroxidase-conjugated Fc-specific goat anti-human IgG 
F(ab')2 Specificity , n OD SD SEM %CV 
Anti-HLA-All 52 0.048 0.003 0.0005 7.12 
Anti-HLA-A24 52 0.055 0.004 0.0006 7.23 
Anti-HLA-A2 + A28 54 0.041 0.005 0.0007 13.40 
Anti-HLA-B17 63 0.048 0.005 0.0006 9.58 
Anti-HLA-Bw22+B7 49 0.063 0.005 0.0008 8.70 
Anti-HLA-B40+B13 52 0.046 0.003 0.0005 7.08 
Anti-HLA-DR2 50 0.046 0.006 0.0008 12.20 
Anti-HLA-DR4 38 0.056 0.005 0.0008 8.52 
Anti-HLA-DR7 51 0.041 0.005 0.0007 11.40 
Reagent Blank 50 0.044 0.006 0.00^8 n .70 
I where : 
1 n = number of tests 
OD = Mean Absorbance 
SD = Standard Deviation 
SEM = Standard Error of Mean 
%CV = Coefficient of Variation in percentage 
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3.4. Discussion 
Even though the yield of IgG from 9 human anti-HLA antisera after 
affinity chromatography purification and the F(ab')2 preparations after pepsin 
digestion were not quite high, they were adequate as a source of ligand in the 
subsequent ELISA. 
The employment of 100 uL of 2 ug/mL F(ab')2 preparations of 9 affinity-
purified human polyclonal anti-HLA antibodies in microplate coating was 
checked being valid and efficiently suitable for anti-Ids detection. The Fab 
specificity was retained without any apparently noticeable deterioration of 
immunochemistry as shown by the goat anti-human Fab reactivity. Moreover, 
the background OD caused by the interference of the likely residual Fc-
contamination in these working F(ab')2 preparations were insignificant and 






















4. ELISA Optimization 
4,1. Coating F(ab')2 Quantitation 
The checkerboard plot (Figure 4.1) shows the mean OD of quadruple 
analyses from titrations of 100 uL of 1，2，5，10 to 20 ug/mL specific anti-HLA 
F(ab')2 with Fc-specific HRP-conjugated goat anti-human IgG of dilutions from 
1:5000 to 1:40000. OD value not greater than 0.05 was chosen as a set point for 
tolerably nominal background interference. High background OD readings 
were observed in over-coated microplates with anti-HLA F(ab')2 preparations 
greater than 0.5 ug. F(ab')2 preparations of 5 ug/mL or higher concentration 
were thus considered inappropriate for use. 
The anti-HLA F(ab02 preparation of 1 ug/mL gave comparatively low 
OD with Fab-specific AP-AHG at manufacturer-recommended working 
concentration of 1:2000 (Table 4.1). 
i •i 
4 Anti-HLA F(ab')2 preparation, at concentration of 2 ug/mL, which 
.A 
exhibited a characteristic of relatively higher anti-Fab binding (Table 4.1) with I 
I comparatively lower background interference (Figure 4.1) was considered the 
optimal coating concentration. It was eventually selected for microplate coating 
for all subsequently assays, 
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Reciprocal HRP-AHG Dilution x 10000 
1 ug/mL H— 2 ug/mL 5 ug/mL 
- e - 10 U g / m L 2 0 Ug/mL 
Figure 4.1. Interaction between F(ab')2 coating concentration for ELISA wells 
and the working dilution of Fc-specific HRP-AHG. 
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！ I Table 4.1. Comparison of mean absorbance of F(ab')2 preparations detected by alkaline phosphatase-coiyugated Fab-specific goat anti-human IgG. 
Concentration (ug/mL) of 
F(ab')2 Preparation 
F(ab')2 Specificity 1 2 
HLA-All 0.193 0.274 
Anti-HLA-A24 0.181 0.253 
Anti-HLA-A2+A28 0.192 0.275 
Anti-HLA-B17 0.180 0.255 
Anti-HLA-Bw22+B7 0.195 0.278 
Anti-HLA-B40+B13 0.191 0.271 
Anti-HLA-DR2 0.186 0.258 
Anti-HLA-DR4 0.203 0.283 
I 
Anti-HLA-DR7 0.178 0.248 
Reagent Blank 0.110 0.104 
I 
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4.2. Blocking and Diluting Agent Concentration 
The efficacy in the blocking of non-specific binding by 1% bovine serum 
albumin (BSA) was compared with 2.5% casein both in 200 uL PBS pH 7.4 
(Figure 4.2). The mean OD of the OPD substrate at 492 nm, from quadruple 
wells, developed after 7-minute incubation by the non-specific binding of 100 uL 
HRP-AHG of dilutions from 1:20000 to 1:40000 in PBS pH 7.4, on plain 
microplates without any anti-HLA F(ab02 coating, and blocked with 2.5% PBSC 
at 37°C for 1 hour, was found more superior than that of 1% BSA under the 
same condition. Moreover, the non-specific binding was further decreased with 
the dilution of HRP-AHG being made in 0.5% PBSC. OD values around 0.05 
were consistently obtained (Figure 4.2). 
4.3. Serum Analyte Dilution 
In order to elucidate the optimal working dilution for serum analyte, 
titrations from 1:50 to 1:400，of a serum sample known to have high anti-F(ab')2 
activity, were made against anti-HLA F(ab')2 preparations of concentration 1， 
2，5，10 and 20 ug/mL separately. Figure 4.3 shows the mean OD of quadruple 
tests detected with HRP-AHG conjugate at 1:30000. 
j 
Two-component curves were shown with a relatively rapid decline of OD 
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• H 1% BSA 2.5% PBSC ffiS 2.5%PBSC+0.5%PBSC 
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Figure 4.2. Comparison of the efficacy of 1% BSA and 2.5% PBSC in blocking 
non-specific binding. Further improvement was acquired with 0.5% PBSC 
being used as diluent. 
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from serum dilutions of 1:50 to 1:100, then followed by a gradual flattening at 
1:200 onwards. Dilution of serum analyte at 1:100 stood out to be the optimal 
one with all 5 anti-HLA F(ab')2 preparations (Figure 4.3). 
4,4. Conjugated Detector Antibody Titration 
It has already been shown that the dilution of 1:30000 stood out to be the 
optimal working concentration of Fc-specific HRP-AHG in giving insignificantly 
low background interference with pre-determined levels of anti-HLA F(ab')2 
preparations (Figure 4.1). 
The manufacturer's recommended working dilution range of the 
conjugated detector antibody is from 1:5000 to 100000. Evaluation of an 
optimal working dilution was performed with 1:100 of a serum sample 
previously known with high anti-F(ab')2 activity (Figure 4.4). A 2-coinponent 
i 
curve, with a comparatively sharp decline at serum dilutions from 1:5000 to 
1:25000, and eventually followed by a onward gentle flattening, was again 
noted. 
The Fc-specific HRP-AHG at 1:30000 was established in this 
experimental setting as the optimal working dilution with respect to an 
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Figure 4.4. Titration of Fc-specific HRP-AHG against a serum of known anti-
F(ab')2 activity at 1:100 dilution in microplate wells coated with 0.2 ug anti-
HLA F(ab')2 preparation. 
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i 1 I 
prospective Ab! in 1:100 dilution of serum analyte. 
4,5, Discussion 
Less than adequate coating of the microplate will reduce sensitivity and 
afford non-specific binding opportunities for the analyte and the conjugated 
detector antibody to the plastic microplate well and eventually leads to high 
backgrounds. However, over-coating induces non-specific trapping�". High 
signal-to-noise ratios are imperative for good sensitivity in all ELISA tests 
(Figure 4.5). The selected quantity of 0.2 ug anti-HLA F(ab')2 for plate coating 
fulfils the target - low background but no compromised sensitivity! 
Proteins do differ considerably in their ability to block non-specific 
binding. Being dispersed or solubilized in water to form micelles, amphipathic 
proteins, such as casein, which contain both strongly non-polar and mighty 
polar groups are especially effective in preventing non-specific bindingus. i^g 
ability of casein in blocking non-specific binding may be attributed to the 
formation of a mono-molecular layer that prevents almost all other protein 
adsorption to the plastics. 
The choice of blocking agent in an attempt to inhibit non-specific binding 
can be critical to the sensitivity and specificity of ELISA system"\ Casein has 
s 
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Figure 4.5. The likely residual Fc-fragments contamination in the ligand Ab^  
F(ab')2 preparation may cause untoward noise generation. Optimization of the 
ELISA system to produce high signal-to-noise ratio is prerequisite, 
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been documented to be a more effective blocking agent than either BSA or 
gelatin"^. Yet blocking proteins are largely chosen by convenience and 
empirical testing in specific ELISA settings. The blocking with 2.5% PBSC 
together with dilutions of serum analytes and conjugated antibody in 0.5% 
PBSC showed that there was apparently no room for the traditional employment 
of BSA in this particular experimental situation. 
The optimal dilution of serum analyte should cover and give a clear 
differentiation of OD values with various degrees of Abj positivity, be capable 
and sensitive enough to detect weakly positive samples and yet exhibit low 
background interference. Data in Figure 4.3 showed that serum dilution at 
1:100 or lower, just below those higher dilutions which generated an apparent 
OD flattening, were preferred because of higher reactivity. However, serum 
diluted at 1:50 inevitably gave unwanted high background interference of non-
specific binding. 
Besides the prerequisite product specificity, the primary criterion for the 
optimal dilution of the conjugated detector antibody, HRP-AHG should exhibit 
a high signal-to-noise ratio, i.e. perfect sensitivity to detect minute amount of 
specific analyte, and yet generate low background from the F(ab')2 preparation 
with likely residual Fc contamination. The ideal ratio of positive signal to 
background at working dilution should be 10:1 or greater"®. 
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The empirical optimization of coating F(ab')2 quantitation, blocking and 
diluting agent concentration, serum analyte dilution and conjugated detector 
antibody titration in the ELISA established the rigid experimental setting for the 










5. Quality Control 
5.1 • Avoidance of Prozone Phenomenon 
Comparison of mean OD at 492 nm, generated from quadruple analyses, 
of a serum sample known to have high anti-FCabOz reactivity and a normal 
control serum, was made at dilutions from 1:50 to 1:400. Data from microplate 
wells which were coated with 0.2 ug anti-HLA F(ab')2 and detected with 1:30000 
Fc-specific HRP-AHG conjugate, showed that there was no evidence of any 
prozone phenomenon (Figure 5.1). Two-component curves, with a 
comparatively rapid decline from 1:50 to 1:100 dilution and an apparent 
flattening of OD from dilutions of 1:200 onwards, were again observed. The 
pre-determined optimized ELISA setting demonstrated a clear discrimination 
between strong and weak signals without any unwanted prozone phenomena. 
i 
1 • i • 1 . 
j • . 
5.2. Inter-assay and Intra-assay Precision 
The intra-assay precision was evaluated by performing 18 to 23 replicate 
analyses of a control serum with high anti-F(ab')2 reactivity in a single batch, 
on microplate wells coated separately with 100 uL of 9 anti-HLA r(ab')2 
preparations of 2 ug/mL (Table 5.1). The inter-assay precision was basically 
performed in parallel with test samples and tested by examining the same 
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Figure 5.1. Titration and comparison of a serum analyte with high anti-F(ab')2 
activity and a normal control serum. 
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Table 5.1. Intra-assay Precision on control serum sample. 
I 
Intra-assay Precision 
Anti-Idiotypes against n OD SD SEM %CV 
Anti-HLA-All 18 1.139 0.051 0.012 4.47 
Anti-HLA-A24 19 1.040 0.070 0.016 6.73 
Anti-HLA-A2+A28 22 1.307 0.044 0.009 3.36 
Anti-HLA-B17 20 1.155 0.052 0.012 4.50 
Anti-HLA-Bw22+B7 21 1.320 0.059 0.013 4.46 
Anti-HLA-B40+B13 22 1.140 0.069 0.015 6.05 
Anti-HLA-DR2 18 1.023 0.037 0.009 3.61 
Anti-HLA-DR4 23 1.210 0.033 0.007 2.72 
Anti-HLA-DR7 19 1.118 0.062 0.014 5.54 
where : 
n = number of tests 
OD = Mean Absorbance 
SD = Standard Deviation 
SEM = Standard Error of Mean 
%CV = Coefficient of Variation in percentage 
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control serum of high anti-F(ab')2 reactivity 10 to 11 times, duplicate on each 
occasion, for the 9 anti-HLA F(ab')2 preparations (Table 5.2). 
The reproducibility of the whole project was properly guarded. The 
%CV values given by the control serum on 9 coating anti-HLA F(ab')2 ligands 
were well below 10; ranging from 2.72 to 6.73 for intra-assay and 3.70 to 8.00 
for inter-assay. There was also no significant difference in the mean OD of the 





I ； Antigen-antibody complex formation is subject to the prozone 
j I 
I 
phenomena. When antigen in appropriate quantity is allowed to react with a 
fixed amount of antibody, a point is reached at which the immune complex 
appears most rapidly and abundantly. Conversely, if an increasingly large 
amount of antigen is permitted to react with a decreasing quantity of antibody, 
a point is reached at which no immune complex is visualized. It is important 
since the non-appearance of immune complex in such experimental setting may 
be erroneously regarded as negative or weak end-point. Employment of suitable 
or multiple dilutions can avoid these untoward phenomena. 
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Table 5.2. Inter-assay precision on control serum sample. 
Inter-assay Precision 
Anti-Idiotypes against n OD SD SEM %CV 
Anti-HLA-All 22 1.181 0.067 0.014 5,67 
Anti-HLA.A24 22 1.161 0.043 0.009 3.70 
Anti-HLA-A2+A28 22 1.255 0.062 0.014 4.94 
Anti-HLA-B17 20 1.194 0.073 0.016 6.11 
1 Anti-HLA-Bw22+B7 22 1.307 0.053 0.011 4.05 
j Anti-HLA-B40+B13 22 1.192 0.065 0.014 5.45 
Anti-HLA-DR2 20 1.079 0.047 0.011 4.35 
Anti-HLA-DR7 20 1.250 0.100 0.022 8.00 
where : 
n = number of tests 
OD = Mean Absorbance 
SD = Standard Deviation 
SEM = Standard Error of Mean 
%CV = Coefficient of Variation in percentage 
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Data in Figure 5.1 show that the pre-determined experimental setting, 
including the dilution of serum analyte at 1:100，was so designed that prozone 
phenomenon was unlikely to go undetected, and good differentiation between 
strong and weak reactions could be achieved within sensitive working OD range, 
without any compromises in sensitivity of the relatively weak end-points 
presumably generated by normal controls. 
Due to the non-availability of suitable commercial and in-house anti-Ids 
standards, the absolute quantitation of anti-Ids was rendered impossible in this 
project. Instead, a semi-quantitative analysis, based upon the numeric values 
of OD generated by the captured Anti-Ids, was adopted to investigate the level 
of anti-Ids production in the study groups. The significance of the OD values 
was put into perspective by comparing them with those from normal controls. 
The occurrence of relatively higher Anti-Ids in transfused renal transplant 
patients was so determined. Statistical manipulation was subsequently made to 
explore possible correlation of Anti-Ids level wkh rejection episodes and graft 
survival. 
I I 
Enzyme immunoassay is vulnerable to experimental deviation and 
inconsistency. The intra-assay and inter-assay precision in this study played a 
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6. Adjustment of Anti-casein Interference 
It is known that anti-casein can be found in the general population, and 
may be especially to those who are intolerant to dairy products^*'. These anti-
casein antibodies have been known to cause interference in detecting humoral 
antibodies by the ELISA. As part of this project, anti-casein antibodies were 
investigated, so that their interference in the analyses of anti-Ids could be 
eliminated. 
6.1. Casein Allergy 
Casein is the principal protein of milk, the basis of curd and cheese. It 
belongs to the family of phospho-protein in which the phosphate prosthetic 
I group esterifies to serine residues of its protein back-bone. It is precipitated 
from milk as a white amorphous substance by dilute acids, however redissolves 
on the addition of alkalis or an excess of acid. Rennet and calcium change it 
to an insoluble curd. 
More or less, all ingested food proteins are likely to be allergenic to a 
certain degree, though they normally lead to no seriously adverse effects. Food 
ingestant-induced nominal minor allergic discomfort may take on a variety of 
forms; such as nausea, vomiting and diarrhoea. Factors dominating the severity 
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of allergy are the level of sensitization, type of allergic sensitivity, extent of 
allergen absorption from gut and antibody isotype as well. Among the broad 
spectrum of ingested food allergens, casein is one of the culprits"，. 
The type of protein in diet may influence directly the intrinsic capacity 
of B lymphocytes to respond to an immunogenic stimulus*^®. Formation of 
antibodies against casein may reflect a normal natural humoral response. 
Recently Harris and his co-workers in Pennsylvania studied the ontogeny of the 
antibody response to cow milk proteins on 29 infants and found that breast-fed 
infants demonstrated significantly lower level of these specific antibodies than 
infants who took milk formula or breast milk with formula supplementation^^*. 
Though precise data on the intolerance of cow milk and/or milk products 
are not available in Hong Kong ethnic Chinese, an anecdotal high incidence has 
been widely speculated. The postulation comes from the apparent dislike of 
dairy products in diets among Chinese. 
The majority of the inhabitants of Hong Kong were mostly economic and 
political migrants. They were ethnic Han and Hakka Chinese from the southern 
provinces of mainland China during the second world war in the early 40s 
followed by the civil war. During those years and years after, the social 
economical environment in Hong Kong was primitive, and breast-feeding was 
the only form of nutrition available to infants. Subsequent immunization to 
� 79 
casual dairy products during their adolescence would be obvious. 
In more recent years, because of tremendous booming of the local 
economy and the progressive improvement of the standard of living as well as 
the impact of "westernization", breast-feeding hardly further sustained its 
popularity. Formula milk feeding was gradually preferred in the sense that it 
allows mothers being gainfully employed to subsidize the family incomes. 
Formula milk feeding also represents a status symbol for young mothers of the 
modern era. Hence, dairy products are relatively new to the gastro-intestinal 
system among ethnic Chinese in Hong Kong. 
Physiological and genetic factors, together with the fact that Chinese are, 
in general，intolerant to dairy foodstuffs, are reasons to presume that the 
prevalence of anti-casein among Hong Kong Chinese is high. 
6.2. Prevalence of Anti-casein 
A semi-qualitative method was adopted to analyze the presence of anti-
casein in each of the 31 serum samples from normal controls and 151 serum 
samples from the 101 transplant patients studied. Duplicate analyses were 
performed in parallel with the detection of anti-Ids against 9 Ab: (see Method 
section 2.2.4). The OD of OPD, from a total of 18 replicate analyses on 9 
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occasions, generated by the putative anti-casein in each serum analyte, were 
read at 492 nm against the reagent blank. 
An arbitrary OD value greater than 0.01, after reagent blank 
adjustment, which is well beyond 3 SD of mean OD value of the negative 
samples (0.001 土 0.006)，was established in this project as the cut-off point to 
indicate the presence of anti-casein antibody. 
Table 6.1 shows the prevalence of anti-casein with mean OD reading 
greater than 0.01. Relatively strong anti-casein was encountered in LD 
transplant group. The overall incidence of anti-casein detected was 23.48% 
(31/132). In both CD and LD transplant recipients, the percentage of anti-
casein encountered was 24.75% (25/101). 
6,3. Discussion 
Inference drawn from the data showed that ELISA-detectable anti-casein 
antibodies were commonly encountered in the Hong Kong Chinese population. 
In order to make adjustment for the interference caused by the putative anti-
casein antibodies in the anti-Ids studies, dilutions of serum analytes were made 
in 0.5% PBSC. Anti-casein antibodies would be neutralized and inhibited. In 
addition, background OD generated by anti-casein was determined for each 
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Control Graft Graft 
Number of studies 31 48 53 
Number of studies with OD > 0.01 5 10 14 
Maximum OD encountered 0.120 0.144 0.693 
Mean OD from group with OD > 0.01 0.065 0.073 0.173 
Percentage of Anti-casein 19.35 20.83 28.30 
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AbiF(ab')2 Ab- Fc-specific 
I® 
o 八 + 。 … 一 
Casein Anti-casein Fc-specific 
HRP-AHG 
Figure 6.1. The interference caused by putative anti-casein in serum analyte 
should be eliminated from the signal generated by Abj, 
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serum studied, and was subtracted to yield a genuine OD reading for the anti-
Ids present (Figure 6.1). 
There have been reports on the association of morbidity with the 
detection of anti-casein. Recently the correlation of circulating immune 
complexes containing bovine proteins and graft-versus host disease is noted^^ .^ 
Transplant recipients with graft-versus-host disease are found more likely to 
have higher antibodies against bovine casein and circulating casein immune 
complexes than patients without this complication. 
In untreated coeliac patients, comparatively elevated titre of antibodies 
to casein is encountered. Moreover, significantly higher quantities of antibody 
to casein are observed even in treated coeliac patients as compared with the 
normal controls^^ .^ 
Effort was made in this project to investigate whether there was any 
association of anti-casein immunization to end-stage renal failure requiring 
transplantation. The x^  analysis for 2 x 2 contingency table in Table 6.2 (x^  = 
0,744; p > 0.25) demonstrates that there was insufficient evidence to reject the 
null hypothesis. Anti-casein immunization and end-stage renal failure requiring 
transplantation were independent variables and not related. 
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Table 6.2. Chi-squared test for 2 x 2 contingency table (x^ = 0.384; p > 0.25) 
shows that there is no correlation of anti-casein immunization to end-stage renal 
failure requiring transplantation. 
Anti-casein detected 
Renal Transplantation Yes No Total 
Yes 25 76 101 
No 6 ^ 31 










7. Prevalence of Anti-idiotypic Antibodies 
7,1. Formation Kinetics 
A total of 5436 anti-Ids assays were done on 151 serum samples from 101 
renal graft recipients against 9 different anti-HLA idiotypes. Temporal study 
j was feasible in 26 (3 not transfused and 23 transfused) patients, whose weekly 
i serum samples were available for periodic anti-Ids assays. The number of days, i ‘ 
at which serum samples generated the highest level of anti-Ids as measured by 
OD at 492 nm, was plotted into a histogram showing the percentage of patients 
with peak anti-Ids level at the same time interval after transplantation (Figure 
7.1). A right-skew pattern of distribution was observed with pinnacle at post-
transplant time interval at 51 to 100 days, then followed by a gentle decline and 
eventually a level off. Thirty eight percent (10/26) of the peak anti-Ids detected 
were encountered in the early 100 days after transplantation. 
12. Occurrence in Transplant Patients 
Anti-Ids assays were done in quadruple on each of the 76 serum samples 
of 48 patients transplanted with CD kidney and 75 serum specimen of 53 LD 
renal graft recipients. For those patients whose temporal study of anti-Ids were 
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I highest OD was enrolled into the statistical manipulation for comparison. The 1 
levels of anti-Ids against 9 anti-HLA antibodies which were chosen to cover the 
) 
most frequent antigens of HLA-A, HLA-B and HLA-DR loci in both CD and 
LD renal grafts, were compared with 31 apparently healthy normal subjects 
who had never been transfused and received any organ transplant (Table 7.1 -
7.9). Comparisons of anti-Ids prevalence were also made in patients receiving 
kidney grafts specific to each of the 9 Ab^ and the patients receiving random 
renal grafts of known and unknown HLA typing with those of normal controls 
of random HLA phenotyping. 
In the investigation of anti-Ids against idiotopes of anti-HLA antibodies 
to antigens in HLA-A locus, data in Table 7.1 show that significantly high level 
of anti-Ids against anti-HLA-A11 was encountered in HLA-All negative, 
cadaveric renal graft recipients either receiving mismatched HLA-All positive 
grafts (Mean OD 0.774 vs 0.322; p < 0.01) or grafts of random antigen in 
HLA-A locus (0.572 vs 0.322; p < 0.01). However, in HLA-All negative, LD 
renal graft recipients who were transplanted with HLA-All positive kidney, 
insignificant increase of anti-Ids was noted in comparison with normal control 
(0.525 vs 0.322; p < 0.1). On the other hand, the HLA-All negative, LD 
transplant patients receiving renal grafts of random antigen in HLA-A locus, 
were found exhibiting notably high level of anti-Ids against idiotopes of anti-
HLA-All antibody (0.577 vs 0.322; p < 0.002). 
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Table 7.1. Comparison of OD of anti-Ids against anti-HLA-All antibody in 
HLA-All negative renal transplant patients with OD from normal controls of 
random HLA phenotypes. 
HLA-A Typing 
Control Cadaver Living Donor 
Random A l l Random A l l Random 
n 31 3 33 5 26 
Mean OD 0.322 0.774 0.572 0.525 0.577 
Variance 0.055 0.079 0.144 0.036 0.109 
Statistics NA' 3.145 3.191 1.834 3.301 
p Value ^ <0.01 <0.01 <0.1 <0.002 
* Not applicable 
� 
� 90 
There was no significant elevation of anti-Ids in both CD and LD kidney 
recipients in whom recipient-donor combination was mismatched for HLA-A24 
and/or other HLA-A locus antigens (Table 7.2). 
In recipient-donor combination with HLA-A2 or HLA-A28 or both 
disparity (Table 7.3), increased quantity of anti-Ids was found in patients 
transplanted with HLA-A2 or HLA-A28 positive CD grafts (p < 0.05) and 
grafts of random antigen in HLA-A locus (p < 0.02). On the contrary, 
comparable amounts of anti-Ids were observed in LD transplant patients after 
transplantation of either HLA-A2 or HLA-A28 positive grafts (0.193 vs 0.387; 
p > 0.1) or other HLA-A locus disparate antigens (0.433 vs 0.387; p < 0.1). 
In the analyses of anti-Ids against idiotopes of anti-HLA antibodies to 
antigens in HLA-B locus, CD and LD kidney transplant recipients of negative 
HLA-B17, who had been transplanted with HLA-B17 positive grafts or grafts 
of other HLA-B typings, had no significant elevation (p > 0.1) in anti-Ids 
against anti-HLA-B17 as compared with normal controls (Table 7.4). 
The quantitative comparison of anti-Ids against anti-HLA-Bw22+B7 
antibody in HLA-Bw22 negative or HLA-B7 negative or both negative renal 
transplant patients is shown in Table 7.5. In patients transplanted with HLA-
Bw22 positive or HLA-B7 positive CD kidney, significantly high level of anti-Ids 
was detected (0.589 vs 0.353; p < 0.05). Similar to HLA-Bw22 positive and 
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Table 7.2. Comparison of OD of anti-Ids against anti-HLA-A24 antibody in 
HLA-A24 negative renal transplant patients with OD from normal controls of 
random HLA phenotypes. 
HLA-A Typing 
Control Cadaver Living Donor 
Random A24 Random A24 Random 
n 31 9 40 3 42 
Mean OD 0.317 0.488 0.430 0.189 0.374 
Variance 0.042 0.118 0.086 0.020 0.073 
Statistics NA' 1.875 1.909 1.050 1.025 
p Value NA <0.1 <0.1 >0.1 >0.1 
* Not applicable 
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Table 7.3. Comparison of OD of anti-Ids against anti-HLA-A2+A28 antibody 
in HLA-A2 negative or HLA-A28 negative or both negative renal transplant 
patients with OD from normal controls of random HLA phenotypes. 
HLA-A Typing 
Control Cadaver Living Donor 
A2/ A2/ 
Random A28 Random A28 Random 
n 31 5 48 5 53 
Mean OD 0.387 0.657 0.563 0.193 0.433 
Variance 0.063 0.124 0.126 0.015 0.121 
Statistics NA* 2.115 2.579 1.681 1.89才 
p Value NA <0.05 <0.02 >0.1 <0.1 
* Not applicable t F distribution 
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Table 7.4. Comparison of OD of anti-Ids against anti-HLA-B17 antibody in 
HLA-B17 negative renal transplant patients with OD of normal controls of 
random HLA phenotypes. 
HLA-B Typing 
Control Cadaver Living Donor 
Random B17 Random B17 Random 
n 31 5 43 7 48 
Mean OD 0.301 0.362 0.362 0.358 0.313 
Variance 0.075 0.112 0.081 0.142 0.085 
Test Statistics NA* 0.449 0.930 0.464 0.185 
p Value NA >0.1 >0.1 >0.1 >0.1 
* Not applicable 
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Table 7.5. Comparison of OD of anti-Ids against anti-HLA-Bw22+B7 antibody 
in HLA-Bw22 negative or HLA-B7 negative or both negative renal transplant 
patients with OD of normal controls of random HLA phenotypes. 
HLA-B Typing 
Control Cadaver Living Donor 
Bw22 Bw22 
Random /B7 Random /B7 Random 
n 31 5 48 3 53 
Mean OD 0.353 0.589 0.605 0.598 0.601 
Variance 0.052 0.098 0.143 0.057 0.132 
Test Statistic NA: 2.044 3.693 1.772 3.841 
p Value NA <0.05 <0.001 <0.1 <0.001 
* Not applicable 
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HLA-B7 positive grafts, grafts of random antigen in the HLA-B locus were also 
capable to elicit anti-Ids response against public cross-reactive idiotopes resided 
on anti-HLA-Bw22+B7, in both CD kidney recipients (0.605 vs 0.353; p < 
0.001) and LD transplant patients (0.601 vs 0.353; p < 0.001). 
In the study of anti-Ids against anti-HLA-B40+B13, modest increase of 
anti-Ids was encountered in LD transplant patients as compared with those of 
the control group (Table 7.6). In addition to HLA-B40 positive and HLA-B13 
positive grafts, patients receiving CD grafts of random HLA-B antigens have 
significantly elevated anti-Ids detected (p < 0.05). 
In the examination of anti-Ids against the idiotopes of anti-HLA 
antibodies to antigens in HLA-DR locus, there were no significant elevations of 
anti-Ids to anti-HLA-DR2, in both CD and LD kidney recipients whom 
recipient-donor combination was mismatched for HLA-DR2 and/or other HLA-
DR locus antigens (Table 7.7). However, notably increase of anti-Ids against the 
idiotopes of anti-HLA-DR4 developed in both CD graft recipients (0.431 vs 
t .'. V , .. .... ••‘ • 0.307; p < 6.05) and LD transplant patients (0.497 vs 0.307; p < 0.01) of 
negative HLA-DR4 receiving grafts of random HLA-DR antigen. 
In the appraisal of anti-Ids against anti-HLA-DR7 (Table 7.9), significant 
raise of anti-Ids was observed in patients receiving HLA-DR7 positive LD grafts 
(0.776 vs 0.351; p < 0.01). Irrespective of the graft HLA-DR typing, both 
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Table 7.6. Comparison of OD of anti-Ids against anti-HLA-B40+B13 antibody 
in HLA-B40 negative or HLA-B13 negative or both negative renal transplant 
patients with OD from normal controls of random HLA phenotypes. 
HLA-B Typing 
Control Cadaver Living Donor 
B40/ B40/ 
Random B13 Random B13 Random 
n 31 3 47 6 50 
Mean OD 0.367 0.548 0.509 0.467 0.483 
Variance 0.061 0.115 0.112 0.046 0.100 
Test Statistics NA* 1.180 2.153 0.924 1.842 
p Value NA >0.1 <0.05 >0.1 <0.1 
* Not applicable 
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Table 7.7. Comparison of OD of anti-Ids against anti-HLA-DR2 antibody in 
HLA-DR2 negative renal transplant patients with OD from normal controls of 
random HLA phenotypes. 
HLA-DR Typing 
Control Cadaver Living Donor 
Random DR2 Random DR2 Random 
n 31 8 43 2 45 
Mean OD 0.293 0.468 0.364 0.263 0.330 
Variance 0.042 0.088 0.071 0.020 0.069 
Test Statistics NA' 1.960 1.295 0.202 0.688 
p Value ^ <0.1 >0.1 >0.1 >0.1 
* Not applicable 
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Table 7.8. Comparison of OD of anti-Ids against anti-HLA-DR4 antibody in 
HLA-DR4 negative renal transplant patients with OD from normal controls of 
random HLA phenotypes. 
HLA-DR Typing 
Control Cadaver Living Donor 
Random Random DR4 Random 
n 31 35 2 40 
Mean Absorbance 0.307 0.431 0.312 0.497 
Variance 0.047 0.075 0.004 0.093 
Test Statistics NA* 2.050 0.032 3.066 
p Value NA <0.05 >0.1 <0.01 
* Not applicable 
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Table 7.9. Comparison of OD of anti-Ids against anti-HLA-DR7 antibody in 
HLA-DR7 negative renal transplant patients with OD from normal controls of 
random HLA phenotypes. 
HLA-DR Typing 
Control Cadaver Living Donor 
Random DR7 Random DR7 Random 
n 31 2 47 3 51 
Mean OD 0.351 0.629 0.525 0.776 0.485 
Variance 0.059 0.245 0.128 0.015 0.103 
Statistics NA" 1.495 2.558 2.964 2.139 
p Value NA >0.1 <0.02 <0.01 <0.05 
* Not applicable 
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recipients of CD or LD renal grafts experienced significantly high level of anti-
Ids to idiotopes of anti-HLA-DR7. 
Patients receiving CD renal graft were more predisposed to anti-Ids 
activation in idiotypic-antiidiotypic interactions than LD renal graft recipients. 
Table 7.10 shows that the prevalence of significant increase of anti-Ids to anti-
HLA antibodies specific to the graft HLA antigens was more frequently 
encountered in CD kidney recipients than LD renal transplant patients (3/8 vs 
1/9). The same also applied to kidney transplantation of random grafts rather 
than planned HLA-matched grafts (6/9 vs 4/9). 
7.3, Transfusion effect 
Blood transfusion was regarded here either as the infusion of either 
random (third party) donations of whole blood, plasma-reduced blood and/or 
platelet concentrates anticoagulated with CPDA-1 solution supplied by Hong 
Kong Red Cross Blood Transfusion Centre or related donor-specific (single 
donor) donations. Other blood products; fresh frozen plasma and cryo-
precipitates, were not defined as blood transfusion in this project. Buffy coats 
were given to anyone in the patient population studied. 



























































































































































































project. The association of transfusion on anti-Ids response in renal transplant 
patients was studied and compared under these stipulations. 
7.3.1. Comparison between Transfused Transplant Patients 
and Normal Controls 
The effect of blood transfusion on the induction of ant-Ids response in 
renal transplant recipients was studied according to the various transfusion 
modalities namely: pre-transplant transfusion, peroperative transfusion and 
post-transplant transfusion. The quantitation, as defined by the magnitude of 
OD, of anti-Ids against each of the 9 anti-HLA antibodies in the transplant 
patients manipulated with different transfusion modalities, was compared with 
normal subjects who have never been transfused and transplanted (Table 7.11 -
7.19). 
Significantly high level of anti-Ids against anti-HLA-All was observed 
in pre-transplant transfused and post-transplant transfused CD kidney 
recipients. Conversely no significant increase in the level of anti-Ids was 
encountered in non-transfused CD kidney recipients (Table 7.11), hence 
transplantation per se did not appear to trigger an significantly high anti-Ids 
response. Comparable anti-Ids level was obtained also in peroperatively 


































































































































































































































































































































































































































































higher anti-Ids level developed in both transfused and non-transfused patients 
when compared with normal controls. There was insufficient evidence to 
indicate, one way or the other, whether transfusion was responsible for the 
increased anti-Ids formation. 
Table 7.12 shows the transfusion effect on the enhancement of anti-Ids 
to anti-HLA-A24 antibody. Significantly higher anti-Ids quantity was detected 
in pre- and post-transplant transfused CD kidney recipients (p < 0.05), but not 
in peroperatively transfused patients ip > 0.10). The level of anti-Ids detected 
in non-transfused CD kidney recipients was slightly higher than that of normal 
controls (0.380 vs 0.317), and did not reach a statistically significant level {p > 
0.10). Also, there was no significant difference of anti-Ids in transfused and 
non-transfused LD transplant patients {p > 0.10). 
Similar findings occurred in anti-Ids against anti-HLA-A2+A28 (Table 
7.13), with the exception that non-pre-transplant transfused LD recipients 
acquired significantly elevated anti-Ids (0.820 vs 0.424; p < 0.02). 
For anti-Ids against anti-HLA-B17 antibodies, comparable OD values 
withp > 0.10 were observed in both transfused and non-transfused CD and LD 
transplant recipients (Table 7.14), inferring that there was insufficient evidence 
to reject the null hypothesis that blood transfusion and increased anti-Ids 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.15 shows significant increase of anti-Ids against anti-HLA-
Bw22+B7 in pre-transplant transfused {p < 0.001) and post-transplant 
transfused (p < 0.01) CD kidney recipients. No significant increase of anti-Ids 
level was seen in peroperatively transfused CD kidney recipients {p > 0.10). 
Anti-Ids level in non-transfused CD kidney recipients was higher, but the 
elevation did not reach a statistically significant level (0.508 vs 0.353; p < 0.10). 
Furthermore, in LD transplant recipients statistically significant increase in 
anti-Ids levels were developed in both the transfused and non-transfused 
patients. 
There were no significant increase, in terms of OD values, of anti-Ids 
against anti-HLA-B40+B13 in both transfused and non-transfused LD 
transplant patients as compared with normal controls, though a small cluster 
of non-pre-transplant transfused patients showed statistically significant 
elevation of anti-Ids (Table 7.16). This would probably be due to sampling bias, 
which could also be observed in anti-Ids against anti-HLA-DR2 (Table 7.17) and 
anti-HLA-DR7 (Table 7.19). 
In the study of anti-Ids to anti-HLA-DR4 (Table 7.18), significantly high 
OD values were observed in both transfused CD and LD kidney recipients. 
Non-transfused CD and LD transplant patients showed comparable level of anti-
Ids to anti-HLA-DR4 to that of normal control (0.323 vs 0.307; p > 0.1, 0.462 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.20 shows the summary of occurrence of significant increase in 
level of anti-Ids against 9 anti-HLA antibodies encountered in CD and LD 
transplant patients. Transfusion-induced enhancement of anti-Ids was more 
frequently observed in CD transplant patients than LD transplant patients (6/9 
vs 3/9), Pre-transplant (7/9) and post-transplant (8/9) transfusion were both 
proficient in triggering the production of anti-Ids; however, peroperative 
transfusion was totally ineffective (0/9). Non-transfused CD kidney recipients 
had statistically insignificant high anti-Ids levels (8/9) when compared with the 
non-transfused, non-transplanted normal controls. On the other hand, 
significantly high anti-Ids levels in non-transfused LD transplant patients were 
encountered in 2 out of the 9 anti-HLA antibodies studied. Whether this 
increase of anti-Ids level to the 2 anti-HLA antibodies was due to sampling bias 
or to a unique phenomenon which outweighed the transfusion effect in LD 
transplant patients, could not be ascertained. 
7.3.2. Comparison between Transfused Transplant Patients 
and Non-transfused Transplant Patients 
Table 7.11 to Table 7.19 have clearly shown that significantly elevated 
levels of anti-Ids were observed in transfused renal transplant patients but 
comparable and statistically insignificant levels of anti-Ids were detected in non-












































































































































































































































































































































be interesting to further expand the observation of transfusion effect on anti-Ids 
induction in transfused and non-transfused transplant patients. 
Table 7.21 to Table 7.29 show the comparison of anti-Ids level in 
transfused and non-transfused CD and LD kidney recipients, and the impact of 
the various transfusion modalities on anti-Ids formation. Anti-Ids against 9 
anti-HLA antibodies in transfused CD transplant patients were all higher than 
those of their non-transfused counterparts, though the increase did not reach 
the 5% significance level. On the contrary, statistically insignificant lower anti-
Ids levels in LD transplant recipients were found in 7 out of the 9 anti-HLA 
antibodies studied. 
7.3.3. Association with Graft Survival 
Transfusion-induced anti-Ids and their association with renal allograft 
survival could only be evaluated in CD transplant recipients. The similar study 
in LD transplant patients was not applicable due to small patient clusters after 
statistical stratifications, despite data of graft failure and transfusion status were 
available. 
Table 7.30 shows the comparison of anti-Ids to the 9 anti-HLA antibodies 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Patients were negative for the HLA to which each of the 9 anti-HLA antibodies 
reacted. The anti-Ids levels were in general comparable. There was insufficient 
evidence to reject the null hypothesis at 5% significance level: anti-Ids in 
transfused patients with successful grafts should be higher than those in 
transfused patients with graft failure. 
Comparisons of anti-Ids levels were also made in transfused and non-
transfused CD kidney recipients with graft failures (Table 7.31). Anti-Ids to 
anti-HLA-All was the only anti-Ids which showed statistically significant 
difference (0.855 vs 0.440; p < 0.05). 
Anti-Ids levels in transfused transplant patients with successful grafts and 
non-transfused kidney recipients with graft failure were also compared (Table 
7.32) and found to be comparable (p > 0.10). There was again insufficient 
evidence to reject the null hypothesis at 5% significance level; indicating that 
anti-Ids in transfused patients with successful grafts were not higher than those 
in non-transfused patients with graft failure. 
7.4. Discussion 
In Jerne's immune network concepts' ,^ anti-Ids are, in fact, immuno-


























































































































































































































































































































































































































































































































































































































































































































of the immune response. The introduction of external antigens disrupts and 
upsets the state of equilibrium of idiotypic-antiidiotypic interactions. The 
emergence of the corresponding antibodies specific to the challenging antigens, 
in turn, activates the proliferation of anti-Ids until the system again returns to 
its state of stability. 
Most of the complementarity-determining amino acid residues of an 
antibody, which function in binding are the surfaces not directly involved in 
bindingi24. They are exposed and become available as antigenic determinants. 
They could very well share determinants with the surfaces of a receptor for the 
same ligand. Anti-Ids directed against these antibody determinants can cross-
react with receptors specific for the same ligand. Data in this study 
demonstrated the presence of anti-Ids against the public, cross-reactive idiotopes 
of the 9 anti-HLA antibodies in both the allogeneic renal transplant recipients 
and the apparently healthy normal subjects, hence they supported Jerne's 
general immune network theory which utilizes idiotypic determinants to 
recognize and regulate the immune response. 
The maximal level of anti-idiotypic antibodies against anti-HLA 
antibodies occurred over a range of pre-transplant and post-transplant time 
intervals. However, according to the limited data in this project, most patients 
reached their peak anti-Ids level in the first 100 days after transplantation 
(Figure 7.1). This is also the post-transplant period when the renal allograft is 
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most susceptible to acute rejection^^ .^ It is possible that the increase in 
formation of anti-Ids during such period when renal allograft is so vulnerable 
to acute rejection, is not merely incidental, but rather it is the way of the 
immune system to respond to a novel antigenic challenge. This surge in anti-Ids 
production may play a role in tolerating or rejecting the graft, depending on 
which way the balance is tipped. 
It is not surprising to observe circulating cross-reactive anti-Ids in normal 
subjects who have no history of transfusion or organ transplantation， 
considering the abundant naturally occurring substances which can mimic 
biologically active ligands. 
It has been reported that Ab�存 which direct to the private (unique) 
idiotopes are particularly low in quantity^^ .^ Though effort has not been made 
to differentiate and classify the anti-Ids encountered in this project, data in 
Table 7.10 show that the incidence of detecting significantly high anti-Ids levels 
in patients having renal allografts of random HLA was comparatively more 
frequent as compared with those having HLA specific graft to which the 9 anti-
HLA antibodies reacted (6/9 vs 3/8 in CD transplants and 4/9 vs 1/9 in LD 
transplants). This paradoxical finding can be explained by the likelihood of 
being sensitized to the public idiotopes in patients having received renal allograft 
of random HLA. The elicited anti-Ids which directed against the cross-reactive 
idiotypes of the anti-HLA antibodies studied, would probably be predominated 
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with Ab2« in nature, and lesser amount of Abj^ specific to the paratopes of the 
9 anti-HLA antibodies existed. It is possible that the minute quantity of Abj^ 
generated was beyond the sensitivity of the ELISA used in this project. 
Chemiluminescent enzyme immunoassay^^^ which is 100 times more sensitive 
than ELISA, can be employed as an alternative to detect this scantiness of Ab�卢. 
LD transplant patients were found less likely to produce significantly 
high anti-Ids when compared to CD transplant patients (4/9 in LD transplant 
vs 6/9 in CD transplant; Table 7.10). This may be attributed to the inferior 
chance of alloimmunization of anti-HLA antibodies to disparate HLA by the 
intended HLA matching of donor-recipient pair. The majority of LD transplant 
are either HLA-identical or single-haplotype identical, and occasional HLA-
disparate, in the sense that antigens in HLA-A, B and DR loci can be matched 
as far as possible and negative MLR is obtained^^ .^ It is understandable that 
cross-reactive anti-Ids to public idiotopes of the 9 anti-HLA antibodies did exist 
in LD transplant recipients, however the planned HLA-matching has restrained 
the relative predisposition of cross-reactive idiotopes immunization to a great 
extent. 
Interestingly, it has been shown that the beneficial effect of transfusion 
will disappear if HLA-DR matching is practised in recipient-donor pairs, and 
the beneficial transfusion effect is most profound when HLA-DR matching is not 
used32，40. Transfusion has been shown to contribute no improvement in graft 
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survival in a series of CD kidney transplant patients who had all been HLA-DR 
niatchedi29. The inference is simply that HLA-DR matching overshadows the 
observation of transfusion effect. For transfusion is regarded as religious 
convictions as in Jehovah's witnesses^ ^®, and in people simply resent homologous 
transfusion for fears of blood borne transmissible diseases, attention to HLA-
matching between donor and recipient is an alternative to transfusion to achieve 
the same beneficial goal in enhancing graft survival if transfusion is precluded 
in renal transplantation. 
Goulmy and co-workers^^^ reported non-reactivity of post-transplant 
donor-specific cell-mediated lympholysis in renal allograft recipients with 
peroperative transfusions. The development of anti-Ids to those donor-specific 
antibodies in allo-sensitized recipients could contribute to the loss of exhibiting 
specific anti-HLA antibodies^^^. Furthermore, in a study of peroperative 
transfusions on the outcome of CD renal transplantation, acceptable graft 
survival rates were obtained^^ .^ 
Data in this study showed that peroperative transfusion was 
comparatively inferior with its counterparts (pre-transplant transfusion and 
post-transplant transfusion) in provoking anti-Ids; none of the 18 comparisons 
in CD renal recipients (Table 7.11 -7.19 and Table 7.21 - 7.29) demonstrated 
significantly high anti-Ids against the 9 anti-HLA antibodies. The lack of 
anamnestic response could be the appropriate explanation to this phenomenon, 
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The introduction of Ab^ in pre-transplant transfusion acts as primary 
stimulation in the immune response, and yields bunches of Ab�memory clones 
and small quantity of Ab�. The subsequent implantation of the renal graft 
triggers the Ab�memory clones and results a significant Ab�proliferation. The 
same explanation can also apply to the increase of anti-Ids in post-transplant 
transfusion with the allograft as primary stimulation and transfusion as the 
second. 
Apparently the conclusion drawn from data in Table 7.11 to Table 7.19 
is incompatible with the inference drawn from data in Table 7.21 to Table 7.29. 
It appears that the elevation of anti-Ids levels was statistically significant only 
between transfused transplant patients and healthy subjects, notable but not 
statistically significant between a) transfused transplant patients and non-
transfused transplant patients, and b) non-transfused transplant patients and 
healthy subjects (Figure 7.2). The simple explanation for this discrepancy is 
that the increase in anti-Ids level, as measured by ELISA under this 
experimental setting, is in small increments being not considered as statistically 
significant. The elevation of anti-Ids level in the transfused transplant patients 
represents the cumulation of multiple small increments which becomes 
statistically significant. Hence, response to antigenic stimulation from anti-HLA 
Abi 括 a stepwise increment in anti-Ids production. Some increments occur 
after transfusion; some more after transplant. The prerequisite of the 
anamnestic response through the subsequent immunological challenge would also 
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Anti—Ids level detected 
"" * * 
I NS • “ ‘ 
- I 1 
:i r_ I 
T NT NC TNT 
T = Transfused Transplant Patients 
N T = Non-Transfused Transplant Patients 
N C = Non-Transfused & Not Transplanted Normal Controls 
T N T = Transplant Patients irrespective of Transfusion Status 
* = Significant Increase 
N S = Non-significant Increase 
Figure 7.2, Schematic presentation of the transfusion-induced stepwise elevation 
of anti-Ids in renal transplant patients. 
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account for the significant increase of anti-Ids observed in transfused transplant 
patients. 
Abi-potentiating antibodies (Abj) against anti-Ids (Ab�）might account for 
the graft failure in transfused transplant patients by potentiating the detrimental 
action of Ab^ against Abf specific antigen in the renal graft. In Table 7.31, 
data suggest that the insignificantly high mean OD values generated by the 
serum analytes of transfused CD transplant recipients with graft failure, in the 
anti-Ids assay using anti-HLA Ab^ as ligand might not be necessarily attributed 
to the markedly increase of anti-Ids against anti-HLA Ab .^ It is possible that 
the profound proliferation of the Abi-potentiating antibodies, Abj, in the form 
of Ab2-Ab3 circulating immune complex, can account for this observation. 
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Chapter 8 
Correlation of Transfusion 
with 
the Outcome of Transplant 
V 
8- Correlation of Transfusion with the Outcome of Transplant 
8.1. Rejection Episode 
Graft rejection referred in this project included acute and chronic 
rejections. Clinical presentations involved persistent oligoanuria and 
azotemiai2s. 
The histologic findings in post-transplant renal biopsy diagnosed as acute 
cellular rejection involved tubulointerstitial nephritis with oedema and cortical 
infiltration by lymphocytes, plasma cells, histiocytes and immunoblasts, and 
invasion of the tubule basement membrane as well as tubule necrosis. Acute 
vascular rejection was characterized in renal biopsy by foci of fibrinoid necrosis 
or intimal fibrin deposition in the walls of arterioles and small arteries. 
In chronic rejection, progressive azotemia, proteinuria and hypertension 
were the clinical hallmarks. Histologically glomeruli were small with wrinkled 
or thickened basement membranes or increased mesangial matrix. Some 
glomeruli were completely hyalinized or sclerosed. Vascular changes included 
intimal proliferation with luminal obliteration and medial necrosis with 
degenerative changes of the internal elastic lamina. Tubule atrophy with 
luminal obliteration and interstitial fibrosis were also seen. 
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Patients with complete record of rejection episodes and transfusion 
history were assorted into 2 groups according to their transfusion history; 
transfused and non-transfused. Table 8.1 shows that rejection happened more 
frequent in non-transfused than transfused cadaveric kidney recipients (p < 
0.05)• There was no significant difference of rejection episodes encountered in 
LD kidney recipients {p >0.05). The overall rejection episodes were 
significantly higher in non-transfused transplant patients {p < 0.01). 
8.2. Graft Survival 
Graft failure was considered to have occurred when patients returned to 
maintenance dialysis therapy, graft nephrectomy, or death with or without a 
functioning graft. 
Of 101 transplant patients studied, the graft failure rates were 5.66% 
(3/52) and 20.83% (10/48) for LD renal allograft recipients and CD kidney 
recipients respectively. The overall failure rate was 12.87% (13/101). CD 
kidney recipients were 3.68 times more likely to experience graft failure as 
compared to their LD transplant counterparts (10/48 in CD transplant vs 3/53 
in LD transplant). Chi-squared analysis of the data in Table 8.2 shows that 














































































































































































Table 8.2. Chi-squared test for 2 x 2 contingency table (x^ = 4.340; p < 0.05) 
shows that graft survival is related to transfusion. 
Transfusion 
Graft Status ^ ^ Total 
Survival 75 13 88 
Failure 8 5 13 
Total ^ 101 
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8.3. Discussion 
Interestingly, the average number of rejection episodes per patient in this 
study was comparatively higher than those reported elsewhere^^^ The increased 
graft survival has been found to result from decreased graft rejection, and not 
apparently related to other differences among patients receiving various types 
of blood^ .^ The finding of reduced acute rejection after 1 or more random 
transfusions suggests that a non-specific effect is induced by crossing a major 
histocompatibility antigen barrieri^s. Susceptibility to early renal allograft 
rejection episodes in renal transplantation of Jehovah's witnesses is another 
evidence of the beneficial effect of transfusion reducing rejection episodes^ ^®. On 
the contrary, Melzer and co-workers showed that transfusions did not alter the 
number of rejection episodes, but did reduce the severity of rejections^^ .^ 
An increased peak MLR to donor and/or third-party has been shown to 
link with early (< 3 days) rejection crises, and a significant proportion of 
transplant patients with donor-specific transfusion plus azathioprine-
immunosuppression had a decreased MLR response^ .^ Elevation of serum 
C-reactive protein levels during graft rejection is also reported*^ .^ 
Scornik and co-workers'^^ demonstrated that anti-donor antibodies, 
predominantly IgG, were detected in 40% post-transplant patients close to the 
time of rejection and 9% of non-rejecting patients, but these antibodies were 
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exclusively IgM. Post-transplant cytotoxic antibody reactivity against panel cells 
developed or increased in some patients, yet it did not correlate with rejection. 
Previous sensitization and post-transplant transfusions favour the development 
of post-transplant panel reactivity but not of anti-donor antibodies. Anti-donor 
antibodies are postulated as being the culprit involved in a significant 
proportion of rejection episodes, however the damage induced does not 
necessarily culminate in the loss of the graft. 
Not only does the frequency of rejection episodes influence renal graft 
survival, but also the severity of rejection plays much role. Relatively scarce 
data exist in the literature concerning the difference in the frequency of 
rejection episodes between transfused and non-transfused renal transplant 
patients. In this study there has been convincing data to suggest that rejection 
episodes are less frequent in the transfused transplant patients (Table 8.1). This 
information can be valuable to health care professionals in renal 
transplantation, since it verifies the fact that transfusion can be used as an 
alternative to the much more expensive anti-rejection drugs when it comes to 
reducing rejection episodes. The beneficial effect of transfusion in reducing 
rejection severity^^^ would also be another incentive to alleviate rejection 
complications, hence medical resources could be better utilized. 
However, the inference must be considered in the light of the 
concomitant effect of the immunosuppressive drug on the frequency of rejection 
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episodes in transfused transplant patients. Azathioprine and prednisolone were 
conventionally used for prophylactic immunosuppression in the early days 
(Table 8.3) Starting October of 1987, cyclosporin was then routinely 
prescribed, in conjunction with prednisolone and/or azathioprine for 
mismatched CD or LD transplants. In a study, it was shown that the number 
of rejection episodes per patient after transplantation was significantly higher 
in patients transfused with 5 units of blood, and were managed with 
azathioprine and prednisone than those transfused with only 0 to 2 units of 
blood but given cyclosporin and prednisone, though no statistically significant 
difference in graft survival existed between them*^ .^ 
The total number of renal transplants done in the 3 major public renal 
dialysis and transplant centres, namely: Princess Margaret Hospital, Queen 
Mary Hospital and Prince of Wales Hospital, between years 1984 and 1991，was 
357 with 152 CD transplants and 205 LD transplants*^ ®'^ ^^ The 101 patients 
enrolled in this study were either in-patients, out-patients or patients who had 
had renal transplants done overseas (PRC, USA and UK), and later returned 
to the medical renal unit of Princess Margaret Hospital for follow-up. Table 8.4 
shows the general information of patients recruited in this study. The sample 
size of this study was 28.29% (101/357) of the total transplants done locally from 
the inception of the renal transplant programme up to the end of 1991. 
It is striking to observe that the graft failure rate in CD transplant was 
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Table 8.3. Statistics of kidney transplants performed in Hong Kong and the 
number of patients on haemodialysis in years 1984 - 1991. 
Number of Number of Source of Graft Year Patients on Patients 丫. . ~ Haemodialysis Transplanted Cadaver Living Donor 
1984 394 31 4 27 
1985 465 35 13 22 
1986 525 40 12 28 
1987 674 44 18 26 
1988 784 52 17 35 
1989 1002 48 24 24 
1990 1100 55 32 23 
199 1 i m ^ n 20 
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Table 8.4. Generat information of patients recruited in this study. 
Renal Transplant Patients 
receiving 
Cadaver Donor Living Donor 
Graft graft 
Number of studies 48 53 
Ratio of Male to Female 2.43 : 1 2.31 : 1 
Age Range (Year) 23 to 54 15 to 53 
Graft Survival Range (Year) Vx to 22 Vz to 19 
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nearly 4-fold higher that of LD transplant. Part of the reason for this 
observation could be quite a number of patients who had received CD 
transplant in mainland China, and these recipients might not have received the 
same standard of care as the local transplant patients. The first year mortality 
rate of these patients was also 4 times that of transplants done local 
Moreover, there was marked increase in post-transplant morbidity related to 
chronic hepatitis B and hepatitis C infections^'*^ 
This study confirmed the beneficial effect of transfusion in renal 
transplantation and supported the hypothesis of transfusion-induced immuno-
modulation of anti-Ids in renal transplantation. Transfused renal transplant 
recipients had significantly lesser rejection episodes and better graft survival 
than their non-transfused counterparts. The results were also in line with other 
similar reports�，i36. 
Bucini"^ reserved conditionally that enhanced graft survival was only 
compiled with HLA-A incompatibility and with HLA-B compatibility among 
transfused patients. In his analysis of the effects of pre-transplant transfusion 
in 116 patients whose 2-year survival after transplantation were significantly 
lower in transfused than non-transfused patients, he reported that transfusion 
might even have detrimental effect on patient survival. Likewise, Kerman and 
co-workersi4s illustrated that the beneficial transfusion effect could also be 
achieved in 100 non-transfused CD kidney recipients managed by cyclosporin 
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and prednisone immunosuppressive therapy. However, they also demonstrated 
that the matchings of HLA-A, HLA-B and HLA-DR antigens played no role, 
and immunosuppressive therapy alone was effective in primary CD renal 





9. General Conclusions 
Despite general acceptance of the benefits of pre-transplant transfusion 
and the development of rational conditioning protocols for transfusion, the 
precise mechanism of the beneficial effect remains vague and obscure. The 
majority of hypotheses cannot adequately explain all the observed phenomena, 
and many of them probably only work in certain experimental settings. 
The study of transfusion effect, based upon the quantitation of anti-Ids 
to the 9 anti-HLA antibodies in this project, demonstrated the beneficial effect 
of blood transfusion in renal transplantation. In addition, the reduced average 
rejection episodes per patient and the enhancement of graft survival in 
transfused transplant recipients associated with an increase of anti-Ids levels 
indicated that idiotypes-anti-idiotypes interactions of the network theory of 
immune system may be operative in this instance. 
Renal dysfunction gives rise to a variety of metabolic and haematologic 
disturbances, including anaemia, leucocyte dysfunction, and coagulopathy^"* .^ 
The anaemia of renal failure has been attributed to a relative deficiency of 
erythropoietin. Blood transfusion has long been the conventional clinical 
manifestation to alleviate haematological deficiency in uraemic patients after 
haemodialysis. Recently, with the advent of recombinant human erythro-
poietin '^^ ,^ normalization of haemoglobin can be easily achieved with the 
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administration of this novel stimulating factor, and transfusion may become 
obsolete to display its beneficial effect in renal transplantation. 
Deliberate blood transfusion which has been employed in patients with 
renal disease for virtually 2 decades as a pre-conditioning regime for renal 
transplantation is now under intense criticism and debate. Though the 
improvement of renal graft survival by the immunosuppression of blood 
transfusion has been appreciated, there has been growing concern for 
transfusion transmitted d i s e a s e s t h e adverse effects of transfusion in 
potentiating s e p s i s " 9，d i s s e m i n a t i n g metastasis and enhancing recurrence of 
malignancy^-®. The availability of effective immunosuppressive agents^ ^^  and the 
supply of recombinant human e r y t h r o p o i e t i n " ? as an alternative to transfusion, 
together with the above concerns related to transfusion lead to the necessity of 
re-appraisal of transfusion in the pre-transplant conditioning. 
Donor specific transfusion and cyclosporin are two available immuno-
suppressive strategies to improve graft tolerance in high MLR, single-haplotype 
matched LD transplant, though each has its own drawbacks. The conventional 
strategy of donor specific transfusion may sensitize the recipient to donor 
antigens, precluding transplantation from that donor. Beneficial effect of 
elective transfusion on allograft survival must be weighed against risks of 
sensitization. The concomitant administration of cyclosporin in transfusion has 
been shown to achieve decreased allo-sensitization with no abrogation of anti-Ids 
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formation⑷，however, cyclosporin may escalate graft failure due to 
nephrotoxicit 产�is3 
The beneficial effect of transfusion has lost much its prestige in renal 
graft enhancement since the start of the cyclosporin era, and its effect on graft 
survival is currently under continuous scrutiny. Conflicting reports, ranging 
from demonstrating a beneficial outcome*^ '* to excellent result*^ ^ without 
transfusion, have been published. Enhancement of renal graft survival is a 
multifactorial sequel and the immunosuppressive effect of cyclosporin cannot be 
singly consideredis6. Better patient care may have also attributed to the 
improvement. In addition, the nephrotoxicity of cyclosporin can hardly be 
regarded as a benefit. 
This study demonstrated the potential benefit of blood transfusion in 
renal transplant. There is a political adage which goes "never believe a rumour 
until it is officially denied". Transfusion conditioning regime of prospective 
recipients for renal transplantation has been the subject rife with rumours. The 
denial by some reports of the beneficial effect of transfusion on renal 
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